0001752724-21-258553.txt : 20211124
0001752724-21-258553.hdr.sgml : 20211124
20211124164944
ACCESSION NUMBER: 0001752724-21-258553
CONFORMED SUBMISSION TYPE: NPORT-P
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210930
FILED AS OF DATE: 20211124
PERIOD START: 20211231
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: T. Rowe Price Health Sciences Fund, Inc.
CENTRAL INDEX KEY: 0001002624
IRS NUMBER: 521952906
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: NPORT-P
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-07381
FILM NUMBER: 211447494
BUSINESS ADDRESS:
STREET 1: 100 EAST PRATT STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
BUSINESS PHONE: 410-345-2000
MAIL ADDRESS:
STREET 1: 100 EAST PRATT STREET
CITY: BALTIMORE
STATE: MD
ZIP: 21202
FORMER COMPANY:
FORMER CONFORMED NAME: PRICE T ROWE HEALTH SCIENCES FUND INC
DATE OF NAME CHANGE: 19980513
FORMER COMPANY:
FORMER CONFORMED NAME: PRICE T ROWE HEALTH & LIFE SCIENCES FUND INC
DATE OF NAME CHANGE: 19951023
0001002624
S000002088
T. Rowe Price Health Sciences Fund, Inc.
C000005456
T. Rowe Price Health Sciences Fund, Inc.
PRHSX
C000169937
T. Rowe Price Health Sciences Fund-I Class
THISX
NPORT-P
1
primary_doc.xml
NPORT-P
false
0001002624
XXXXXXXX
S000002088
C000005456
C000169937
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
811-07381
0001002624
549300ELV6FPY6UQBJ78
100 East Pratt Street
Baltimore
21202
410-345-2000
T. Rowe Price Health Sciences Fund, Inc.
S000002088
66LP7EMLZS5S33LWIH41
2021-12-31
2021-09-30
N
19376329627.72
81576711.52
19294752916.20
775903001.81000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
0.00000000
14154210.00000000
0.00000000
0.02000000
N
Zimmer Biomet Holdings Inc
2P2YLDVPES3BXQ1FRB91
Zimmer Biomet Holdings Inc
98956P102
444930.00000000
NS
USD
65119954.80000000
0.337500848457
Long
EC
CORP
US
N
1
N
N
N
GINGKO BIOWORKS HOLDINGS
N/A
GINGKO BIOWORKS HOLDINGS
000000000
547946.00000000
NS
USD
6033159.43000000
0.031268394346
Long
EC
CORP
US
Y
2
N
N
N
Longboard Pharmaceuticals Inc
N/A
Longboard Pharmaceuticals Inc
54300N103
780535.00000000
NS
USD
6954566.85000000
0.036043824350
Long
EC
CORP
US
N
1
N
N
N
Merck & Co Inc
4YV9Y5M8S0BRK1RP0397
Merck & Co Inc
58933Y105
4262646.00000000
NS
USD
320167341.06000000
1.659349266873
Long
EC
CORP
US
N
1
N
N
N
Evotec SE
529900F9KI6OYITO9B12
Evotec SE
000000000
889119.00000000
NS
42159335.97000000
0.218501559222
Long
EC
CORP
DE
N
2
N
N
N
Cerevel Therapeutics Holdings
N/A
Cerevel Therapeutics Holdings Inc
15678U128
1769216.00000000
NS
USD
52191872.00000000
0.270497747375
Long
EC
CORP
US
N
1
N
N
N
BECTON DICKINSON AND CO
ICE2EP6D98PQUILVRZ91
BECTON DICKINSON AND CO
075887109
980714.00000000
NS
USD
241079115.48000000
1.249454276647
Long
EC
CORP
US
N
1
N
N
N
Sartorius AG
529900EQV2DY4FOAMU38
Sartorius AG
000000000
196084.00000000
NS
124828804.68000000
0.646957259427
Long
EP
CORP
DE
N
2
N
N
N
COLOR GENOMICS SER D CVT PFD STOCK PP
N/A
COLOR GENOMICS SER D CVT PFD STOCK PP
000000000
296922.00000000
NS
USD
13596058.38000000
0.070465055650
Long
EP
CORP
US
Y
3
N
N
N
RAPID MICRO BIOSYSTEMS INC
N/A
RAPID MICRO BIOSYSTEMS INC
000000000
370289.00000000
NS
USD
6497275.94000000
0.033673797058
Long
EC
CORP
US
Y
2
N
N
N
Penumbra Inc
549300RGE06P3ECANU72
Penumbra Inc
70975L107
546904.00000000
NS
USD
145749916.00000000
0.755386278502
Long
EC
CORP
US
N
1
N
N
N
Option Care Health Inc
549300DI3Q5ACSYJRI17
Option Care Health Inc
68404L201
1666189.00000000
NS
USD
40421745.14000000
0.209496049602
Long
EC
CORP
US
N
1
N
N
N
Health Sciences Acquisitions C
N/A
Health Sciences Acquisitions Corp 2
000000000
688861.00000000
NS
USD
6812835.29000000
0.035309264231
Long
EC
CORP
US
N
1
N
N
N
Stoke Therapeutics Inc
549300RD25SS2DIJHJ67
Stoke Therapeutics Inc
86150R107
254758.00000000
NS
USD
6481043.52000000
0.033589668383
Long
EC
CORP
US
N
1
N
N
N
Definitive Healthcare Corp
N/A
Definitive Healthcare Corp
24477E103
615230.00000000
NS
USD
26350300.90000000
0.136567184946
Long
EC
CORP
US
N
1
N
N
N
Ortho Clinical Diagnostics Hol
N/A
Ortho Clinical Diagnostics Holdings PLC
000000000
3577780.00000000
NS
USD
66117374.40000000
0.342670231057
Long
EC
CORP
US
N
1
N
N
N
PAX LABS CLASS A COMMON PP
N/A
PAX LABS CLASS A COMMON PP
000000000
8397988.00000000
NS
USD
10665444.76000000
0.055276399787
Long
EC
CORP
US
Y
3
N
N
N
Moderna Inc
549300EI6OKH5K5Q2G38
Moderna Inc
60770K107
1276162.00000000
NS
USD
491143707.32000000
2.545478086467
Long
EC
CORP
US
N
1
N
N
N
Phreesia Inc
5493000HHF8NU4QOCG53
Phreesia Inc
71944F106
1174872.00000000
NS
USD
72489602.40000000
0.375695935132
Long
EC
CORP
US
N
1
N
N
N
Bruker Corp
LEBZ6VLQ6I8XB1NHVY15
Bruker Corp
116794108
2029650.00000000
NS
USD
158515665.00000000
0.821548043079
Long
EC
CORP
US
N
1
N
N
N
Lantheus Holdings Inc
5299005HUB5IOJGO7S39
Lantheus Holdings Inc
516544103
878190.00000000
NS
USD
22551919.20000000
0.116881098700
Long
EC
CORP
US
N
1
N
N
N
Ginkgo Bioworks Holdings, Inc
N/A
Ginkgo Bioworks Holdings, Inc
000000000
7090407.00000000
NS
USD
78068926.27000000
0.404612210423
Long
EC
CORP
US
Y
2
N
N
N
Generation Bio Co
N/A
Generation Bio Co
37148K100
1736219.00000000
NS
USD
43527010.33000000
0.225589881969
Long
EC
CORP
US
N
1
N
N
N
RAPT Therapeutics Inc
549300MB473BIU78ES48
RAPT Therapeutics Inc
75382E109
738777.00000000
NS
USD
22939025.85000000
0.118887378084
Long
EC
CORP
US
N
1
N
N
N
Dexcom Inc
549300YSK3QDSFR5EU59
Dexcom Inc
252131107
284357.00000000
NS
USD
155503469.02000000
0.805936565735
Long
EC
CORP
US
N
1
N
N
N
Zai Lab Ltd
549300P2UYQ9U5LY1T58
Zai Lab Ltd
98887Q104
436922.00000000
NS
USD
46047209.58000000
0.238651460218
Long
EC
CORP
CN
N
1
N
N
N
Humana Inc
529900YLDW34GJAO4J06
Humana Inc
444859102
823804.00000000
NS
USD
320583326.60000000
1.661505218503
Long
EC
CORP
US
N
1
N
N
N
Acceleron Pharma Inc
529900TQRID2UY164805
Acceleron Pharma Inc
00434H108
1692703.00000000
NS
USD
291314186.30000000
1.509810400605
Long
EC
CORP
US
N
1
N
N
N
GENESIS THERA SER A CVT PFD STOCK PP
N/A
GENESIS THERA SER A CVT PFD STOCK PP
000000000
829412.00000000
NS
USD
4236304.73000000
0.021955734537
Long
EP
CORP
US
Y
3
N
N
N
Nevro Corp
254900SH91I4BOYKUE38
Nevro Corp
64157F103
245132.00000000
NS
USD
28528462.16000000
0.147856063686
Long
EC
CORP
US
N
1
N
N
N
Agiliti Inc
N/A
Agiliti Inc
00848J104
1604221.00000000
NS
USD
30544367.84000000
0.158304011316
Long
EC
CORP
US
N
1
N
N
N
PROCEPT BioRobotics Corp
N/A
PROCEPT BioRobotics Corp
74276L105
268312.00000000
NS
USD
10236102.80000000
0.053051225089
Long
EC
CORP
US
N
1
N
N
N
NUTCRACKER THERA SER C CVT PFD STOCK PP
N/A
NUTCRACKER THERA SER C CVT PFD STOCK PP
000000000
1027785.00000000
NS
USD
11050024.87000000
0.057269584731
Long
EP
CORP
US
Y
3
N
N
N
Avidity Biosciences Inc
N/A
Avidity Biosciences Inc
05370A108
963638.00000000
NS
USD
23734403.94000000
0.123009628799
Long
EC
CORP
US
N
1
N
N
N
SPAC CMLT/EQRX PIPE COMMIT PP
N/A
SPAC CMLT/EQRX PIPE COMMIT PP
000000000
884467.00000000
NS
USD
7896521.38000000
0.040925745016
Long
EC
CORP
US
N
2
N
N
N
Burning Rock Biotech Ltd
N/A
Burning Rock Biotech Ltd
12233L107
456624.00000000
NS
USD
8164437.12000000
0.042314286974
Long
EC
CORP
CN
N
1
N
N
N
Genmab A/S
529900MTJPDPE4MHJ122
Genmab A/S
372303206
45647.00000000
NS
USD
1994773.90000000
0.010338426766
Long
EC
CORP
DK
N
1
N
N
N
DELFI DIAGNOSTICS SR A CVT PFD STOCK PP
N/A
DELFI DIAGNOSTICS SR A CVT PFD STOCK PP
000000000
2152801.00000000
NS
USD
4464909.27000000
0.023140536131
Long
EP
CORP
US
Y
3
N
N
N
Acerta Future Payments PP
N/A
Acerta Future Payments PP
000000000
25372878.73000000
NS
USD
22772158.66000000
0.118022546123
Long
EC
CORP
US
Y
3
N
N
N
REFLEXION MEDICAL INC
N/A
REFLEXION MEDICAL INC CVT PFD SR C PP
000000000
2507885.00000000
NS
USD
5717639.24000000
0.029633130130
Long
EP
CORP
US
Y
3
N
N
N
agilon health Inc
N/A
agilon health Inc
00857U107
936437.00000000
NS
USD
24544013.77000000
0.127205639152
Long
EC
CORP
US
N
1
N
N
N
Seres Therapeutics Inc
549300GMXBE5NUWISF13
Seres Therapeutics Inc
81750R102
471039.00000000
NS
USD
3278431.44000000
0.016991310820
Long
EC
CORP
US
N
1
N
N
N
IMAGO BIOSCIENCES INC
N/A
IMAGO BIOSCIENCES INC
000000000
529300.00000000
NS
USD
10071785.05000000
0.052199606254
Long
EC
CORP
US
Y
2
N
N
N
Denali Therapeutics Inc
549300ZTQ2HO18L3Q830
Denali Therapeutics Inc
24823R105
1432855.00000000
NS
USD
72287534.75000000
0.374648667769
Long
EC
CORP
US
N
1
N
N
N
Oak Street Health Inc
2549007CJE6GSEURLA30
Oak Street Health Inc
67181A107
465354.00000000
NS
USD
19791505.62000000
0.102574548147
Long
EC
CORP
US
N
1
N
N
N
Doximity, Inc
N/A
Doximity, Inc
000000000
2071266.00000000
NS
USD
158793607.89000000
0.822988553311
Long
EC
CORP
US
Y
2
N
N
N
LARONDE SERIES B CVT PFD STOCK PP
N/A
LARONDE SERIES B CVT PFD STOCK PP
000000000
1169887.00000000
NS
USD
32756836.00000000
0.169770694355
Long
EP
CORP
US
Y
3
N
N
N
Novavax Inc
529900J4GJHPEPQ23205
Novavax Inc
670002401
291207.00000000
NS
USD
60370123.17000000
0.312883629203
Long
EC
CORP
US
N
1
N
N
N
Berkeley Lights Inc
549300LTLRE4N65CD358
Berkeley Lights Inc
084310101
331312.00000000
NS
USD
6480462.72000000
0.033586658238
Long
EC
CORP
US
N
1
N
N
N
VIVIDION THERAPEUTICS MILESTONE PAYMENT
N/A
VIVIDION THERAPEUTICS MILESTONE PAYMENT
000000000
2328481.81000000
NS
USD
1137696.21000000
0.005896402068
Long
EC
CORP
US
Y
3
N
N
N
IVERIC bio Inc
549300GZXI59U71XPM70
IVERIC bio Inc
46583P102
2537772.00000000
NS
USD
41213417.28000000
0.213599093281
Long
EC
CORP
US
N
1
N
N
N
Sarepta Therapeutics Inc
549300IKDPIED8J8IG21
Sarepta Therapeutics Inc
803607100
279992.00000000
NS
USD
25893660.16000000
0.134200527327
Long
EC
CORP
US
N
1
N
N
N
TEMPUS LAB SERIES G CVT PFD
N/A
TEMPUS LAB SERIES G CVT PFD
000000000
111715.00000000
NS
USD
6461584.43000000
0.033488816664
Long
EP
CORP
US
Y
3
N
N
N
Insulet Corp
549300TZTYD2PYN92D43
Insulet Corp
45784P101
313825.00000000
NS
USD
89198479.75000000
0.462293972549
Long
EC
CORP
US
N
1
N
N
N
Eli Lilly & Co
FRDRIPF3EKNDJ2CQJL29
Eli Lilly & Co
532457108
2243718.00000000
NS
USD
518411043.90000000
2.686798043755
Long
EC
CORP
US
N
1
N
N
N
VIVIDION THERAPEUTICS MILESTONE PAYMENT
N/A
VIVIDION THERAPEUTICS MILESTONE PAYMENT
000000000
1746361.36000000
NS
USD
1023891.67000000
0.005306580884
Long
EC
CORP
US
Y
3
N
N
N
AC Immune SA
967600VLQ0ZC2HSOG765
AC Immune SA
000000000
335619.00000000
NS
USD
2252003.49000000
0.011671585014
Long
EC
CORP
CH
N
1
N
N
N
Karuna Therapeutics Inc
N/A
Karuna Therapeutics Inc
48576A100
427366.00000000
NS
USD
52279682.78000000
0.270952849238
Long
EC
CORP
US
N
1
N
N
N
Agilent Technologies Inc
QUIX8Y7A2WP0XRMW7G29
Agilent Technologies Inc
00846U101
2218531.00000000
NS
USD
349485188.43000000
1.811296521639
Long
EC
CORP
US
N
1
N
N
N
Lonza Group AG
549300EFW4H2TCZ71055
Lonza Group AG
000000000
77808.00000000
NS
58364544.19000000
0.302489202341
Long
EC
CORP
CH
N
2
N
N
N
Incyte Corp
549300Z4WN6JVZ3T4680
Incyte Corp
45337C102
2323016.00000000
NS
USD
159777040.48000000
0.828085444648
Long
EC
CORP
US
N
1
N
N
N
CureVac NV
724500BUT8GAG9LMYN56
CureVac NV
000000000
405872.00000000
NS
USD
22168728.64000000
0.114895115455
Long
EC
CORP
DE
N
1
N
N
N
Neurocrine Biosciences Inc
549300FECER0XBN49756
Neurocrine Biosciences Inc
64125C109
365109.00000000
NS
USD
35017604.19000000
0.181487704673
Long
EC
CORP
US
N
1
N
N
N
T. ROWE PRICE GOVERNMENT RESERVE FUND
5493007QR86JJLYO6D96
T. ROWE PRICE GOVERNMENT RESERVE FUND
000000000
34552325.04000000
NS
USD
34552325.04000000
0.179076276281
Long
STIV
RF
US
N
1
N
N
N
Relay Therapeutics Inc
N/A
Relay Therapeutics Inc
75943R102
312846.00000000
NS
USD
9864034.38000000
0.051122885184
Long
EC
CORP
US
N
1
N
N
N
Scholar Rock Holding Corp
549300Z1FLPGL4OWJ459
Scholar Rock Holding Corp
80706P103
952830.00000000
NS
USD
31462446.60000000
0.163062189687
Long
EC
CORP
US
N
1
N
N
N
Alector Inc
549300Z8RQOIY1JMHC25
Alector Inc
014442107
513521.00000000
NS
USD
11718549.22000000
0.060734383440
Long
EC
CORP
US
N
1
N
N
N
TEMPUS LABS INC
N/A
TEMPUS LABS INC CVT PFD SR D PP
000000000
946886.00000000
NS
USD
52999860.70000000
0.274685355807
Long
EP
CORP
US
Y
3
N
N
N
Enanta Pharmaceuticals Inc
529900SSN4DODDQSN594
Enanta Pharmaceuticals Inc
29251M106
220225.00000000
NS
USD
12510982.25000000
0.064841370627
Long
EC
CORP
US
N
1
N
N
N
Accolade Inc
549300PHKG8J7A22NF08
Accolade Inc
00437E102
444589.00000000
NS
USD
18748318.13000000
0.097167961732
Long
EC
CORP
US
N
1
N
N
N
EXACT SCIENCES FDA MILESTONE PP
N/A
EXACT SCIENCES FDA MILESTONE PP
000000000
1863135.85000000
NS
USD
1490508.68000000
0.007724943078
Long
EC
CORP
US
Y
3
N
N
N
Replimune Group Inc
549300AY704NEIRC4K64
Replimune Group Inc
76029N106
1248619.00000000
NS
USD
37009067.16000000
0.191808971696
Long
EC
CORP
US
N
1
N
N
N
Protagonist Therapeutics Inc
N/A
Protagonist Therapeutics Inc
74366E102
388176.00000000
NS
USD
6878478.72000000
0.035649478124
Long
EC
CORP
US
N
1
N
N
N
THESEUS PHARMA SERIES B CVT PFD STOCK PP
N/A
THESEUS PHARMA SERIES B CVT PFD STOCK PP
000000000
514797.00000000
NS
USD
5837797.98000000
0.030255883583
Long
EP
CORP
US
Y
2
N
N
N
SOMALOGIC INC
N/A
SOMALOGIC INC
000000000
3873442.00000000
NS
USD
45592349.06000000
0.236294029045
Long
EC
CORP
US
Y
2
N
N
N
Abcam PLC
213800B9N83DSNT33F79
Abcam PLC
000000000
1474562.00000000
NS
29555220.27000000
0.153177500631
Long
EC
CORP
GB
N
2
N
N
N
Pacific Biosciences of Califor
N/A
Pacific Biosciences of California Inc
69404D108
2701237.00000000
NS
USD
69016605.35000000
0.357696238193
Long
EC
CORP
US
N
1
N
N
N
PROGNOMIQ SER B CVT PFD STOCK
N/A
PROGNOMIQ SER B CVT PFD STOCK
000000000
3734140.00000000
NS
USD
8532935.59000000
0.044224124698
Long
EP
CORP
US
Y
3
N
N
N
REGENXBIO Inc
549300EOES47LATSET33
REGENXBIO Inc
75901B107
238760.00000000
NS
USD
10008819.20000000
0.051873269605
Long
EC
CORP
US
N
1
N
N
N
KARDIUM INC SER D-5 CVT PFD STOCK PP
N/A
KARDIUM INC SER D-5 CVT PFD STOCK PP
000000000
8849057.00000000
NS
USD
8989226.06000000
0.046588966954
Long
EP
CORP
US
Y
3
N
N
N
TREELINE BIO SER A CVT PFD STOCK PP
N/A
TREELINE BIO SER A CVT PFD STOCK PP
000000000
922369.00000000
NS
USD
7219843.35000000
0.037418687771
Long
EP
CORP
US
Y
3
N
N
N
Quanterix Corp
N/A
Quanterix Corp
74766Q101
596234.00000000
NS
USD
29686490.86000000
0.153857844093
Long
EC
CORP
US
N
1
N
N
N
FREENOME HOLDINGS SER C CVT PFD PP
N/A
FREENOME HOLDINGS SER C CVT PFD PP
000000000
928231.00000000
NS
USD
6138670.07000000
0.031815230268
Long
EP
CORP
US
Y
3
N
N
N
Series A-5 CVT Pfd
N/A
Series A-5 CVT Pfd
000000000
513797.00000000
NS
USD
1174084.72000000
0.006084994843
Long
EP
CORP
US
Y
3
N
N
N
Arvinas Inc
N/A
Arvinas Inc
04335A105
549763.00000000
NS
USD
45179523.34000000
0.234154453991
Long
EC
CORP
US
N
1
N
N
N
Apellis Pharmaceuticals Inc
254900HS0ZFRXXSB9D42
Apellis Pharmaceuticals Inc
03753U106
1237214.00000000
NS
USD
40778573.44000000
0.211345403681
Long
EC
CORP
US
N
1
N
N
N
Eisai Co Ltd
353800HDEE0ZYEX4QV91
Eisai Co Ltd
000000000
345800.00000000
NS
25903007.71000000
0.134248973399
Long
EC
CORP
JP
N
2
N
N
N
Cigna Corp
549300VIWYMSIGT1U456
Cigna Corp
125523100
918399.00000000
NS
USD
183826743.84000000
0.952729193467
Long
EC
CORP
US
N
1
N
N
N
CARIS LIFE SER D CVT PFD STOCK PP
N/A
CARIS LIFE SER D CVT PFD STOCK PP
000000000
2280334.00000000
NS
USD
18470705.40000000
0.095729162639
Long
EP
CORP
US
Y
3
N
N
N
INTUITIVE SURGICAL INC
54930052SRG011710797
INTUITIVE SURGICAL INC
46120E602
738824.00000000
NS
USD
734501879.60000000
3.806744158839
Long
EC
CORP
US
N
1
N
N
N
HONOR TECHNOLOGY SER E CVT PFD STOCK PP
N/A
HONOR TECHNOLOGY SER E CVT PFD STOCK PP
000000000
2095807.00000000
NS
USD
6625684.25000000
0.034339306021
Long
EP
CORP
US
Y
3
N
N
N
ELEMENT BIOSCIENCES SER C CVT PFD STOCK
N/A
ELEMENT BIOSCIENCES SER C CVT PFD STOCK
000000000
861217.00000000
NS
USD
17703779.50000000
0.091754372688
Long
EP
CORP
US
Y
3
N
N
N
DICE Therapeutics Inc
N/A
DICE Therapeutics Inc
23345J104
474448.00000000
NS
USD
15538172.00000000
0.080530557024
Long
EC
CORP
US
N
1
N
N
N
PROCEPT BioRobotics, Inc.
N/A
PROCEPT BioRobotics, Inc.
000000000
694834.00000000
NS
USD
25182521.25000000
0.130514867743
Long
EC
CORP
US
Y
2
N
N
N
PROGENIC PHARMACEUTICALS CVR
N/A
PROGENIC PHARMACEUTICALS CVR
000000000
842223.00000000
NS
USD
40847.82000000
0.000211704291
Long
EC
CORP
US
N
2
N
N
N
Novocure Ltd
213800YPP55UMHWA4826
Novocure Ltd
000000000
563219.00000000
NS
USD
65429151.23000000
0.339103338167
Long
EC
CORP
JE
N
1
N
N
N
Ginkgo Bioworks Holdings Earn Out Shares $17.50 PP
N/A
Ginkgo Bioworks Holdings Earn Out Shares $17.50 PP
000000000
212706.00000000
NS
USD
1638413.48000000
0.008491497595
Long
EC
CORP
US
Y
2
N
N
N
Ginkgo Bioworks Holdings Earn Out Shares $12.50 PP
N/A
Ginkgo Bioworks Holdings Earn Out Shares $12.50 PP
000000000
212707.00000000
NS
USD
1770313.35000000
0.009175102462
Long
EC
CORP
US
Y
2
N
N
N
FLAME BIOSCIENCES INC PP
N/A
FLAME BIOSCIENCES INC PP
000000000
839721.00000000
NS
USD
5500172.55000000
0.028506053297
Long
EC
CORP
US
Y
3
N
N
N
uniQure NV
N/A
uniQure NV
000000000
416122.00000000
NS
USD
13320065.22000000
0.069034650393
Long
EC
CORP
NL
N
1
N
N
N
Xencor Inc
549300V5IF65437JKG30
Xencor Inc
98401F105
988502.00000000
NS
USD
32284475.32000000
0.167322564119
Long
EC
CORP
US
N
1
N
N
N
Prothena Corp PLC
5299009ZXQ8NIIJ8OL30
Prothena Corp PLC
000000000
1006244.00000000
NS
USD
71674760.12000000
0.371472806266
Long
EC
CORP
IE
N
1
N
N
N
Insmed Inc
529900Q55QAG41CCAC11
Insmed Inc
457669307
2287188.00000000
NS
USD
62989157.52000000
0.326457445677
Long
EC
CORP
US
N
1
N
N
N
Monte Rosa Therapeutics Inc
N/A
Monte Rosa Therapeutics Inc
61225M102
393209.00000000
NS
USD
8760696.52000000
0.045404554067
Long
EC
CORP
US
N
1
N
N
N
HONOR TECHNOLOGY SER D CVT PFD PP
N/A
HONOR TECHNOLOGY SER D CVT PFD PP
000000000
3130941.00000000
NS
USD
9898156.88000000
0.051299733782
Long
EP
CORP
US
Y
3
N
N
N
Ascendis Pharma A/S
549300B66JN3W3J8GH73
Ascendis Pharma A/S
04351P101
813997.00000000
NS
USD
129742981.83000000
0.672426241442
Long
EC
CORP
DK
N
1
N
N
N
Allogene Therapeutics Inc
N/A
Allogene Therapeutics Inc
019770106
1213740.00000000
NS
USD
31193118.00000000
0.161666325220
Long
EC
CORP
US
N
1
N
N
N
VIVIDION THERAPEUTICS MILESTONE PAYMENT 3
N/A
VIVIDION THERAPEUTICS MILESTONE PAYMENT 3
000000000
1746361.36000000
NS
USD
710594.44000000
0.003682837728
Long
EC
CORP
US
Y
3
N
N
N
Quidel Corp
549300X2FQ6S98OQLQ46
Quidel Corp
74838J101
436942.00000000
NS
USD
61674363.30000000
0.319643187802
Long
EC
CORP
US
N
1
N
N
N
Akero Therapeutics Inc
549300SI3KG74LBE2955
Akero Therapeutics Inc
00973Y108
320250.00000000
NS
USD
7157587.50000000
0.037096030879
Long
EC
CORP
US
N
1
N
N
N
Alignment Healthcare Inc
N/A
Alignment Healthcare Inc
01625V104
2570009.00000000
NS
USD
41068743.82000000
0.212849286012
Long
EC
CORP
US
N
1
N
N
N
AbbVie Inc
FR5LCKFTG8054YNNRU85
AbbVie Inc
00287Y109
2638952.00000000
NS
USD
284663752.24000000
1.475342822353
Long
EC
CORP
US
N
1
N
N
N
CAPSULE SERIES D CVT PFD STOCK PP
N/A
CAPSULE SERIES D CVT PFD STOCK PP
000000000
853213.00000000
NS
USD
12364421.51000000
0.064081782045
Long
EP
CORP
US
Y
3
N
N
N
Surgery Partners Inc
549300LC82HG33S19I03
Surgery Partners Inc
86881A100
823568.00000000
NS
USD
34869869.12000000
0.180722029825
Long
EC
CORP
US
N
1
N
N
N
COOPER COS INC/THE
QJKMVPIGLH7530PCUE20
COOPER COS INC/THE
216648402
197335.00000000
NS
USD
81560528.85000000
0.422708335287
Long
EC
CORP
US
N
1
N
N
N
GENERATE BIO SER B CVT PFD STOCK PP
N/A
GENERATE BIO SER B CVT PFD STOCK PP
000000000
1864632.00000000
NS
USD
22095889.20000000
0.114517606397
Long
EP
CORP
US
Y
3
N
N
N
FREENOME HOLDINGS SER B CVT PFD PP
N/A
FREENOME HOLDINGS SER B CVT PFD PP
000000000
1558570.00000000
NS
USD
10307290.98000000
0.053420176069
Long
EP
CORP
US
Y
3
N
N
N
Kodiak Sciences Inc
254900IXI5NI8C9OQE24
Kodiak Sciences Inc
50015M109
1364585.00000000
NS
USD
130972868.30000000
0.678800443150
Long
EC
CORP
US
N
1
N
N
N
Regeneron Pharmaceuticals Inc
549300RCBFWIRX3HYQ56
Regeneron Pharmaceuticals Inc
75886F107
447297.00000000
NS
USD
270695198.46000000
1.402947213865
Long
EC
CORP
US
N
1
N
N
N
Ionis Pharmaceuticals Inc
549300SI4ZGLG0BLUZ92
Ionis Pharmaceuticals Inc
462222100
1308767.00000000
NS
USD
43896045.18000000
0.227502499620
Long
EC
CORP
US
N
1
N
N
N
REVOLUTION Medicines Inc
549300JU3X0LBCQ65892
REVOLUTION Medicines Inc
76155X100
848590.00000000
NS
USD
23344710.90000000
0.120989944786
Long
EC
CORP
US
N
1
N
N
N
Ginkgo Bioworks Holdings Earn Out Shares $20.00 PP
N/A
Ginkgo Bioworks Holdings Earn Out Shares $20.00 PP
000000000
212706.00000000
NS
USD
1580726.34000000
0.008192519214
Long
EC
CORP
US
Y
2
N
N
N
INSITRO SER C CVT PFD PP
N/A
INSITRO SER C CVT PFD PP
000000000
588382.00000000
NS
USD
10762154.00000000
0.055777620199
Long
EP
CORP
US
Y
3
N
N
N
Exelixis Inc
254900PJQB59O2O95R37
Exelixis Inc
30161Q104
4276740.00000000
NS
USD
90410283.60000000
0.468574456447
Long
EC
CORP
US
N
1
N
N
N
Prelude Therapeutics Inc
N/A
Prelude Therapeutics Inc
74065P101
328791.00000000
NS
USD
10274718.75000000
0.053251362142
Long
EC
CORP
US
N
1
N
N
N
SomaLogic Inc
549300D3W3Q8CN30YO25
SomaLogic Inc
83444K105
551066.00000000
NS
USD
6827707.74000000
0.035386344513
Long
EC
CORP
US
N
1
N
N
N
Genmab A/S
529900MTJPDPE4MHJ122
Genmab A/S
000000000
216047.00000000
NS
94395670.78000000
0.489229746501
Long
EC
CORP
DK
N
2
N
N
N
Color Genomics Series D-1 CVT Pfd Stock PP
N/A
Color Genomics Series D-1 CVT Pfd Stock PP
000000000
438696.00000000
NS
USD
20087889.84000000
0.104110635296
Long
EP
CORP
US
Y
3
N
N
N
Teleflex Inc
UUL85LWXB4NGSWWXIQ25
Teleflex Inc
879369106
405745.00000000
NS
USD
152783279.75000000
0.791838487974
Long
EC
CORP
US
N
1
N
N
N
Merck KGaA
529900OAREIS0MOPTW25
Merck KGaA
000000000
448395.00000000
NS
97050512.75000000
0.502989145139
Long
EC
CORP
DE
N
2
N
N
N
AADI BIOSCIENCES INC PP
N/A
AADI BIOSCIENCES INC PP
000000000
405655.00000000
NS
USD
11318382.98000000
0.058660419385
Long
EC
CORP
US
Y
2
N
N
N
Mettler-Toledo International I
5493000BD5GJNUDIUG10
Mettler-Toledo International Inc
592688105
45060.00000000
NS
USD
62063841.60000000
0.321661758870
Long
EC
CORP
US
N
1
N
N
N
Seer Inc
N/A
Seer Inc
81578P106
2630514.00000000
NS
USD
90831648.42000000
0.470758287574
Long
EC
CORP
US
N
1
N
N
N
THERMO FISHER SCIENTIFIC INC
HCHV7422L5HDJZCRFL38
THERMO FISHER SCIENTIFIC INC
883556102
1422670.00000000
NS
USD
812814051.10000000
4.212617049983
Long
EC
CORP
US
N
1
N
N
N
Molina Healthcare Inc
549300NQQCEQ46YHZ591
Molina Healthcare Inc
60855R100
665900.00000000
NS
USD
180665329.00000000
0.936344351154
Long
EC
CORP
US
N
1
N
N
N
PTC Therapeutics Inc
549300UJLWOIWFDGB318
PTC Therapeutics Inc
69366J200
414054.00000000
NS
USD
15406949.34000000
0.079850461972
Long
EC
CORP
US
N
1
N
N
N
C4 Therapeutics Inc
N/A
C4 Therapeutics Inc
12529R107
1169227.00000000
NS
USD
52241062.36000000
0.270752689018
Long
EC
CORP
US
N
1
N
N
N
Series A-4 CVT Pfd
N/A
Series A-4 CVT Pfd
000000000
593540.00000000
NS
USD
1356306.56000000
0.007029406211
Long
EP
CORP
US
Y
3
N
N
N
Kronos Bio Inc
N/A
Kronos Bio Inc
50107A104
552898.00000000
NS
USD
11588742.08000000
0.060061624682
Long
EC
CORP
US
N
1
N
N
N
Radius Health Inc
549300EV6I2M6E0YVT27
Radius Health Inc
750469207
507175.00000000
NS
USD
6294041.75000000
0.032620483803
Long
EC
CORP
US
N
1
N
N
N
Ginkgo Bioworks Holdings Earn Out Shares $15.00 PP
N/A
Ginkgo Bioworks Holdings Earn Out Shares $15.00 PP
000000000
212706.00000000
NS
USD
1701031.15000000
0.008816029712
Long
EC
CORP
US
Y
2
N
N
N
TEMPUS LAB SERIES E CVT PFD STOCK PP
N/A
TEMPUS LAB SERIES E CVT PFD STOCK PP
000000000
633505.00000000
NS
USD
36165786.84000000
0.187438455403
Long
EP
CORP
US
Y
3
N
N
N
Centene Corp
549300Z7JJ4TQSQGT333
Centene Corp
15135B101
4396641.00000000
NS
USD
273954700.71000000
1.419840419308
Long
EC
CORP
US
N
1
N
N
N
Iovance Biotherapeutics Inc
549300220Z2GHH33XL82
Iovance Biotherapeutics Inc
462260100
1467698.00000000
NS
USD
36193432.68000000
0.187581737051
Long
EC
CORP
US
N
1
N
N
N
BeiGene Ltd
549300JFUK6FRD5MH739
BeiGene Ltd
07725L102
260250.00000000
NS
USD
94470750.00000000
0.489618863793
Long
EC
CORP
CN
N
1
N
N
N
Shockwave Medical Inc
549300LDXO56IC5Y1538
Shockwave Medical Inc
82489T104
1000171.00000000
NS
USD
205915205.48000000
1.067208304632
Long
EC
CORP
US
N
1
N
N
N
SOMALOGIC INC
N/A
SOMALOGIC INC
000000000
756585.00000000
NS
USD
8905383.74000000
0.046154432651
Long
EC
CORP
US
Y
2
N
N
N
Elanco Animal Health Inc
549300SHPNDCE059M934
Elanco Animal Health Inc
28414H103
930291.00000000
NS
USD
29666979.99000000
0.153756724011
Long
EC
CORP
US
N
1
N
N
N
INSCRIPTA SERIES E CVT PFD STOCK PP
N/A
INSCRIPTA SERIES E CVT PFD STOCK PP
000000000
1452941.00000000
NS
USD
12829469.03000000
0.066492009955
Long
EP
CORP
US
Y
3
N
N
N
Stryker Corp
5493002F0SC4JTBU5137
Stryker Corp
863667101
1682049.00000000
NS
USD
443589962.28000000
2.299018620277
Long
EC
CORP
US
N
1
N
N
N
INSITRO SER B CVT PFD PP
N/A
INSITRO SER B CVT PFD PP
000000000
883580.00000000
NS
USD
16161650.14000000
0.083761892210
Long
EP
CORP
US
Y
3
N
N
N
Kymera Therapeutics Inc
N/A
Kymera Therapeutics Inc
501575104
725304.00000000
NS
USD
42604356.96000000
0.220807994510
Long
EC
CORP
US
N
1
N
N
N
Daiichi Sankyo Co Ltd
353800XGIU2IHQGC9504
Daiichi Sankyo Co Ltd
000000000
1403600.00000000
NS
37309328.90000000
0.193365155086
Long
EC
CORP
JP
N
2
N
N
N
Agios Pharmaceuticals Inc
529900ONJHY8EOGYT555
Agios Pharmaceuticals Inc
00847X104
570909.00000000
NS
USD
26347450.35000000
0.136552411240
Long
EC
CORP
US
N
1
N
N
N
Seagen Inc
N/A
Seagen Inc
81181C104
998710.00000000
NS
USD
169580958.00000000
0.878896758805
Long
EC
CORP
US
N
1
N
N
N
PACIFIC BIOSCIENCES OF CALIFORNIA INC
N/A
PACIFIC BIOSCIENCES OF CALIFORNIA INC
000000000
365964.00000000
NS
USD
8882861.19000000
0.046037703766
Long
EC
CORP
US
Y
2
N
N
N
Roche Holding AG
549300U41AUUVOAAOB37
Roche Holding AG
000000000
431856.00000000
NS
157614472.86000000
0.816877383942
Long
EC
CORP
CH
N
2
N
N
N
Shop Apotheke Europe NV
529900JK6UXHY1YKZ082
Shop Apotheke Europe NV
000000000
68493.00000000
NS
10085863.65000000
0.052272572205
Long
EC
CORP
NL
N
2
N
N
N
Bright Health Group, Inc
N/A
Bright Health Group, Inc
000000000
3127275.00000000
NS
USD
24242635.80000000
0.125643670614
Long
EC
CORP
US
Y
2
N
N
N
Revolution Healthcare Acquisit
N/A
Revolution Healthcare Acquisition Corp
76155Y207
1738886.00000000
NS
USD
17128027.10000000
0.088770388376
Long
EC
CORP
US
N
1
N
N
N
Repligen Corp
54930006QJ0T5AUO1E71
Repligen Corp
759916109
137815.00000000
NS
USD
39827156.85000000
0.206414443465
Long
EC
CORP
US
N
1
N
N
N
Warby Parker Inc
N/A
Warby Parker Inc
93403J106
2443421.00000000
NS
USD
129623484.05000000
0.671806913584
Long
EC
CORP
US
N
1
N
N
N
Vertex Pharmaceuticals Inc
54930015RAQRRZ5ZGJ91
Vertex Pharmaceuticals Inc
92532F100
1558054.00000000
NS
USD
282615415.06000000
1.464726790166
Long
EC
CORP
US
N
1
N
N
N
Ultragenyx Pharmaceutical Inc
529900EV44GVDN1DCX77
Ultragenyx Pharmaceutical Inc
90400D108
1525947.00000000
NS
USD
137625159.93000000
0.713277648735
Long
EC
CORP
US
N
1
N
N
N
CLEAR LABS SERIES C CVT PFD PP
N/A
CLEAR LABS SERIES C CVT PFD PP
000000000
3830773.00000000
NS
USD
13293931.54000000
0.068899205901
Long
EP
CORP
US
Y
3
N
N
N
Wuxi Biologics Cayman Inc
5493001TD2TH6VDTJU11
Wuxi Biologics Cayman Inc
000000000
2865500.00000000
NS
46479258.19000000
0.240890662823
Long
EC
CORP
CN
N
2
N
N
N
AFFINIVAX SERIES C CVT PFD STOCK PP
N/A
AFFINIVAX SERIES C CVT PFD STOCK PP
000000000
424076.00000000
NS
USD
13396306.39000000
0.069429789788
Long
EP
CORP
US
Y
3
N
N
N
Helix Acquisition Corp
N/A
Helix Acquisition Corp
000000000
639149.00000000
NS
USD
6308400.63000000
0.032694902377
Long
EC
CORP
US
N
1
N
N
N
EXACT SCIENCES EXPENSE FUND PP
N/A
EXACT SCIENCES EXPENSE FUND PP
000000000
3795.08000000
NS
USD
3605.33000000
0.000018685546
Long
EC
CORP
US
Y
3
N
N
N
VIVIDION THERAPEUTICS ESCROW PAYMENT
N/A
VIVIDION THERAPEUTICS ESCROW PAYMENT
000000000
291060.23000000
NS
USD
288382.48000000
0.001494616081
Long
EC
CORP
US
N
3
N
N
N
IMMUNEERING CORP
N/A
IMMUNEERING CORP
000000000
974629.00000000
NS
USD
24582579.95000000
0.127405518260
Long
EC
CORP
US
Y
2
N
N
N
Bio-Techne Corp
54930073RLKQ51TILZ35
Bio-Techne Corp
09073M104
118351.00000000
NS
USD
57349344.07000000
0.297227667641
Long
EC
CORP
US
N
1
N
N
N
NATIONAL RESILIENCE SER C CVT PFD STOCK
N/A
NATIONAL RESILIENCE SER C CVT PFD STOCK
000000000
426855.00000000
NS
USD
18956630.55000000
0.098247594215
Long
EP
CORP
US
Y
3
N
N
N
Blueprint Medicines Corp
5299004CC60O9T5HVM83
Blueprint Medicines Corp
09627Y109
730223.00000000
NS
USD
75074226.63000000
0.389091412344
Long
EC
CORP
US
N
1
N
N
N
IGM Biosciences Inc
5493008XCQES2N0VY969
IGM Biosciences Inc
449585108
377037.00000000
NS
USD
24793953.12000000
0.128501013864
Long
EC
CORP
US
N
1
N
N
N
Fate Therapeutics Inc
549300L14Q4UHOODLA90
Fate Therapeutics Inc
31189P102
1206059.00000000
NS
USD
71483116.93000000
0.370479566338
Long
EC
CORP
US
N
1
N
N
N
LIANBIO SERIES A CVT PFD STOCK PP
N/A
LIANBIO SERIES A CVT PFD STOCK PP
000000000
202628.00000000
NS
USD
11480902.48000000
0.059502718328
Long
EP
CORP
US
Y
3
N
N
N
TENAYA THERAPEUTICS INC
N/A
TENAYA THERAPEUTICS INC
000000000
430747.00000000
NS
USD
8450179.27000000
0.043795218869
Long
EC
CORP
US
Y
2
N
N
N
Alkermes PLC
N/A
Alkermes PLC
000000000
76805.00000000
NS
USD
2368666.20000000
0.012276219396
Long
EC
CORP
IE
N
1
N
N
N
Rocket Pharmaceuticals Inc
549300R7VV82YUIN4Y93
Rocket Pharmaceuticals Inc
77313F106
694370.00000000
NS
USD
20754719.30000000
0.107566649804
Long
EC
CORP
US
N
1
N
N
N
Turning Point Therapeutics Inc
N/A
Turning Point Therapeutics Inc
90041T108
531122.00000000
NS
USD
35282434.46000000
0.182860255392
Long
EC
CORP
US
N
1
N
N
N
10X Genomics Inc
5493003Z6741WNLG7H43
10X Genomics Inc
88025U109
503125.00000000
NS
USD
73244937.50000000
0.379610652793
Long
EC
CORP
US
N
1
N
N
N
Veeva Systems Inc
549300YZEXPDB92M2F02
Veeva Systems Inc
922475108
594731.00000000
NS
USD
171383632.27000000
0.888239580026
Long
EC
CORP
US
N
1
N
N
N
AtriCure Inc
N/A
AtriCure Inc
04963C209
305070.00000000
NS
USD
21217618.50000000
0.109965743495
Long
EC
CORP
US
N
1
N
N
N
Alcon Inc
549300LDT5AP8S0NBM78
Alcon Inc
000000000
513245.00000000
NS
41557831.92000000
0.215384110387
Long
EC
CORP
CH
N
2
N
N
N
UNITEDHEALTH GROUP INC
549300GHBMY8T5GXDE41
UNITEDHEALTH GROUP INC
91324P102
2901526.00000000
NS
USD
1133742269.24000000
5.875909757248
Long
EC
CORP
US
N
1
N
N
N
Monte Rosa Therapeutics, Inc.
N/A
Monte Rosa Therapeutics, Inc.
000000000
679381.00000000
NS
USD
14379778.25000000
0.074526884653
Long
EC
CORP
US
Y
2
N
N
N
BioNTech SE
894500UZJ5LG1F8J1U58
BioNTech SE
09075V102
888020.00000000
NS
USD
242420579.80000000
1.256406759147
Long
EC
CORP
DE
N
1
N
N
N
ADC Therapeutics SA
N/A
ADC Therapeutics SA
000000000
1072666.00000000
NS
USD
29133608.56000000
0.150992389933
Long
EC
CORP
CH
N
1
N
N
N
Cortexyme Inc
N/A
Cortexyme Inc
22053A107
65500.00000000
NS
USD
6003730.00000000
0.031115868786
Long
EC
CORP
US
N
1
N
N
N
FOG PHARMACEUTICALS SERIES C CVT PFD STOCK PP
N/A
FOG PHARMACEUTICALS SERIES C CVT PFD STOCK PP
000000000
431391.00000000
NS
USD
6250596.76000000
0.032395319013
Long
EP
CORP
US
Y
3
N
N
N
Quantum-Si Inc
N/A
Quantum-Si Inc
74765K105
1866008.00000000
NS
USD
15562506.72000000
0.080656677945
Long
EC
CORP
US
N
1
N
N
N
Biopharmaceuticals, Inc
N/A
Biopharmaceuticals, Inc
000000000
270332.00000000
NS
USD
6094229.44000000
0.031584905318
Long
EC
CORP
US
Y
2
N
N
N
Multiplan Corp
N/A
Multiplan Corp
62548M100
1988518.00000000
NS
USD
11195356.34000000
0.058022802306
Long
EC
CORP
US
N
1
N
N
N
Inari Medical Inc
N/A
Inari Medical Inc
45332Y109
167497.00000000
NS
USD
13584006.70000000
0.070402594731
Long
EC
CORP
US
N
1
N
N
N
Pennant Group Inc/The
5493007H2OYR6BYLDA64
Pennant Group Inc/The
70805E109
504314.00000000
NS
USD
14166180.26000000
0.073419858349
Long
EC
CORP
US
N
1
N
N
N
SPAC FSII/ PARDES BIO PIPE COMMIT PP
N/A
SPAC FSII/ PARDES BIO PIPE COMMIT PP
000000000
530954.00000000
NS
USD
4754693.07000000
0.024642414912
Long
EC
CORP
US
N
2
N
N
N
Adaptive Biotechnologies Corp
549300ZTF7OT1FW66Q96
Adaptive Biotechnologies Corp
00650F109
1255261.00000000
NS
USD
42666321.39000000
0.221129141043
Long
EC
CORP
US
N
1
N
N
N
Certara Inc
N/A
Certara Inc
15687V109
896790.00000000
NS
USD
29683749.00000000
0.153843633701
Long
EC
CORP
US
N
1
N
N
N
ZENECA INC
N/A
ZENECA (OMTHERA) CVR PP
000000000
375635.00000000
NS
USD
0.00000000
0.000000
Long
EC
CORP
US
Y
3
N
N
N
Nurix Therapeutics Inc
N/A
Nurix Therapeutics Inc
67080M103
710773.00000000
NS
USD
21294759.08000000
0.110365544313
Long
EC
CORP
US
N
1
N
N
N
PRIME MEDICINE SER B CVT PFD STOCK PP
N/A
PRIME MEDICINE SER B CVT PFD STOCK PP
000000000
1625121.00000000
NS
USD
7118517.52000000
0.036893540699
Long
EP
CORP
US
Y
3
N
N
N
ACADIA Pharmaceuticals Inc
529900O3044NO0PEA039
ACADIA Pharmaceuticals Inc
004225108
1096469.00000000
NS
USD
18212350.09000000
0.094390170058
Long
EC
CORP
US
N
1
N
N
N
SOMALOGIC INC EARN OUT SHS $20 PP
N/A
SOMALOGIC INC EARN OUT SHS $20 PP
000000000
3873442.00000000
NS
USD
321450.06000000
0.001665997286
Long
EC
CORP
US
Y
2
N
N
N
DANAHER CORP
S4BKK9OTCEWQ3YHPFM11
DANAHER CORP
235851102
2423520.00000000
NS
USD
737816428.80000000
3.823922659204
Long
EC
CORP
US
N
1
N
N
N
Deciphera Pharmaceuticals Inc
529900QR4WAPYY0CBF25
Deciphera Pharmaceuticals Inc
24344T101
96883.00000000
NS
USD
3292084.34000000
0.017062070472
Long
EC
CORP
US
N
1
N
N
N
MeiraGTx Holdings plc
54930007YV6NYIOGFZ57
MeiraGTx Holdings plc
000000000
494331.00000000
NS
USD
6515282.58000000
0.033767121083
Long
EC
CORP
US
N
1
N
N
N
ALNYLAM PHARMACEUTICALS INC
529900S3ZI14OWRJII50
ALNYLAM PHARMACEUTICALS INC
02043Q107
1202350.00000000
NS
USD
227015703.50000000
1.176567041236
Long
EC
CORP
US
N
1
N
N
N
Outset Medical Inc
N/A
Outset Medical Inc
690145107
641577.00000000
NS
USD
31719566.88000000
0.164394781409
Long
EC
CORP
US
N
1
N
N
N
Amgen Inc
62QBXGPJ34PQ72Z12S66
Amgen Inc
031162100
634354.00000000
NS
USD
134895378.10000000
0.699129855074
Long
EC
CORP
US
N
1
N
N
N
Sophia Genetics SA
N/A
Sophia Genetics SA
000000000
1146130.00000000
NS
USD
20091658.90000000
0.104130169415
Long
EC
CORP
CH
N
1
N
N
N
Royalty Pharma PLC
549300FGFN7VOK8BZR03
Royalty Pharma PLC
000000000
1597128.00000000
NS
USD
57720205.92000000
0.299149754188
Long
EC
CORP
US
N
1
N
N
N
NATIONAL RESILIENCE SER B CVT PFD STOCK
N/A
NATIONAL RESILIENCE SER B CVT PFD STOCK
000000000
1204832.00000000
NS
USD
53506589.12000000
0.277311605659
Long
EP
CORP
US
Y
3
N
N
N
VERILY LIFE SCIENCES LLC SER B UNITS PP
N/A
VERILY LIFE SCIENCES LLC SER B UNITS PP
000000000
113564.00000000
NS
USD
14845086.08000000
0.076938461686
Long
EC
CORP
US
Y
3
N
N
N
SEMA4 HOLDINGS CORP
N/A
CM LIFE SCIENCES INC-A -CW27
81663L119
253101.00000000
NS
USD
536574.12000000
0.002780932838
Long
EC
CORP
US
N
1
N
N
N
Argenx SE
7245009C5FZE6G9ODQ71
Argenx SE
04016X101
824888.00000000
NS
USD
249116176.00000000
1.291108401760
Long
EC
CORP
NL
N
1
N
N
N
Catalent Inc
N/A
Catalent Inc
148806102
804457.00000000
NS
USD
107049092.99000000
0.554809348712
Long
EC
CORP
US
N
1
N
N
N
Imago Biosciences Inc
N/A
Imago Biosciences Inc
45250K107
240093.00000000
NS
USD
4809062.79000000
0.024924199915
Long
EC
CORP
US
N
1
N
N
N
GYROSCOPE THERA SR C-1 CVT PFD
N/A
GYROSCOPE THERA SR C-1 CVT PFD
000000000
3555744.00000000
NS
USD
8178211.20000000
0.042385674672
Long
EP
CORP
US
Y
3
N
N
N
Olink Holding AB
8945004Z7ZHV3LML4J27
Olink Holding AB
680710100
1692804.00000000
NS
USD
41050497.00000000
0.212754717193
Long
EC
CORP
SE
N
1
N
N
N
MaxCyte Inc
54930053YHXULRFCU991
MaxCyte Inc
57777K106
422700.00000000
NS
USD
5161167.00000000
0.026749070187
Long
EC
CORP
US
N
1
N
N
N
Immuneering Corp
N/A
Immuneering Corp
45254E107
401531.00000000
NS
USD
10660648.05000000
0.055251539609
Long
EC
CORP
US
N
1
N
N
N
Doximity Inc
N/A
Doximity Inc
26622P107
574338.00000000
NS
USD
46349076.60000000
0.240215963382
Long
EC
CORP
US
N
1
N
N
N
TEMPUS LABS SERIES G-2 CVT PFD STOCK PP
N/A
TEMPUS LABS SERIES G-2 CVT PFD STOCK PP
000000000
117271.00000000
NS
USD
6720437.47000000
0.034830388858
Long
EP
CORP
US
Y
3
N
N
N
REFLEXION MEDICAL INC CVT
N/A
REFLEXION MEDICAL INC CVT
000000000
1123437.00000000
NS
USD
2561284.70000000
0.013274514118
Long
EP
CORP
US
Y
3
N
N
N
Invitae Corp
549300MYI59DZW1WIX92
Invitae Corp
46185L103
901387.00000000
NS
USD
25626432.41000000
0.132815551053
Long
EC
CORP
US
N
1
N
N
N
Avantor Inc
N/A
Avantor Inc
05352A100
4373940.00000000
NS
USD
178894146.00000000
0.927164741507
Long
EC
CORP
US
N
1
N
N
N
Dicerna Pharmaceuticals Inc
549300CTZMJMPH28WN39
Dicerna Pharmaceuticals Inc
253031108
868406.00000000
NS
USD
17507064.96000000
0.090734849189
Long
EC
CORP
US
N
1
N
N
N
Zymeworks Inc
894500AHOYAGYLYZJL67
Zymeworks Inc
98985W102
490021.00000000
NS
USD
14230209.84000000
0.073751708051
Long
EC
CORP
CA
N
1
N
N
N
Day One Biopharmaceuticals Inc
N/A
Day One Biopharmaceuticals Inc
23954D109
200661.00000000
NS
USD
4761685.53000000
0.024678655128
Long
EC
CORP
US
N
1
N
N
N
Intellia Therapeutics Inc
5493002T5BCPE5DZC723
Intellia Therapeutics Inc
45826J105
475904.00000000
NS
USD
63842521.60000000
0.330880223640
Long
EC
CORP
US
N
1
N
N
N
Rapid Micro Biosystems Inc
N/A
Rapid Micro Biosystems Inc
75340L104
336580.00000000
NS
USD
6216632.60000000
0.032219291052
Long
EC
CORP
US
N
1
N
N
N
Centessa Pharmaceuticals
N/A
Centessa Pharmaceuticals
000000000
649336.00000000
NS
USD
10301715.64000000
0.053391280441
Long
EC
CORP
US
Y
2
N
N
N
Guardant Health Inc
254900M8C3E5VC8BR186
Guardant Health Inc
40131M109
872150.00000000
NS
USD
109027471.50000000
0.565062802169
Long
EC
CORP
US
N
1
N
N
N
ICU Medical Inc
5493003NRW7LS2QZRH60
ICU Medical Inc
44930G107
7833.00000000
NS
USD
1828065.54000000
0.009474417982
Long
EC
CORP
US
N
1
N
N
N
Sema4 Holdings Corp
N/A
Sema4 Holdings Corp
81663L101
1419923.00000000
NS
USD
10777215.57000000
0.055855680644
Long
EC
CORP
US
N
1
N
N
N
TEMPUS LABS SERIES F CVT PFD STOCK PP
N/A
TEMPUS LABS SERIES F CVT PFD STOCK PP
000000000
172826.00000000
NS
USD
9948227.49000000
0.051559237546
Long
EP
CORP
US
Y
3
N
N
N
CRISPR Therapeutics AG
506700O6IRRIQLT3W370
CRISPR Therapeutics AG
000000000
251390.00000000
NS
USD
28138082.70000000
0.145832822126
Long
EC
CORP
CH
N
1
N
N
N
Mersana Therapeutics Inc
529900VWD5VDZ7PVOS22
Mersana Therapeutics Inc
59045L106
241556.00000000
NS
USD
2277873.08000000
0.011805660792
Long
EC
CORP
US
N
1
N
N
N
Immunocore Holdings PLC
213800IUE3DFS84BVN18
Immunocore Holdings PLC
45258D105
304616.00000000
NS
USD
11292115.12000000
0.058524279471
Long
EC
CORP
GB
N
1
N
N
N
Twist Bioscience Corp
549300T23BL59LCOH584
Twist Bioscience Corp
90184D100
398661.00000000
NS
USD
42644767.17000000
0.221017430776
Long
EC
CORP
US
N
1
N
N
N
Schrodinger Inc/United States
N/A
Schrodinger Inc/United States
80810D103
207182.00000000
NS
USD
11328711.76000000
0.058713950933
Long
EC
CORP
US
N
1
N
N
N
- EXACT SCIENCES CMO MILESTONE PP
N/A
- EXACT SCIENCES CMO MILESTONE PP
000000000
3726271.69000000
NS
USD
2981017.35000000
0.015449886106
Long
EC
CORP
US
Y
3
N
N
N
Annexon Inc
N/A
Annexon Inc
03589W102
571522.00000000
NS
USD
10636024.42000000
0.055123921338
Long
EC
CORP
US
N
1
N
N
N
EXACT SCIENCES CORP
549300VM3X1FYD4N9Z14
EXACT SCIENCES CORP
30063P105
1341605.00000000
NS
USD
128056197.25000000
0.663684048228
Long
EC
CORP
US
N
1
N
N
N
Reata Pharmaceuticals Inc
5299005F094GH9QDDD80
Reata Pharmaceuticals Inc
75615P103
186798.00000000
NS
USD
18793746.78000000
0.097403407349
Long
EC
CORP
US
N
1
N
N
N
Global Blood Therapeutics Inc
549300U4G0QKK99GRT15
Global Blood Therapeutics Inc
37890U108
159954.00000000
NS
USD
4075627.92000000
0.021122985807
Long
EC
CORP
US
N
1
N
N
N
BIOGEN INC
W8J5WZB5IY3K0NDQT671
BIOGEN INC
09062X103
526309.00000000
NS
USD
148940183.91000000
0.771920659242
Long
EC
CORP
US
N
1
N
N
N
West Pharmaceutical Services I
5493007NKRGM1RJQ1P16
West Pharmaceutical Services Inc
955306105
652954.00000000
NS
USD
277205091.16000000
1.436686400514
Long
EC
CORP
US
N
1
N
N
N
Mirati Therapeutics Inc
529900GYRW59IDQV6N54
Mirati Therapeutics Inc
60468T105
702359.00000000
NS
USD
124254330.69000000
0.643979900803
Long
EC
CORP
US
N
1
N
N
N
ANTHEM INC
8MYN82XMYQH89CTMTH67
ANTHEM INC
036752103
811789.00000000
NS
USD
302634939.20000000
1.568483102708
Long
EC
CORP
US
N
1
N
N
N
PMV Pharmaceuticals Inc
N/A
PMV Pharmaceuticals Inc
69353Y103
96760.00000000
NS
USD
2883448.00000000
0.014944207953
Long
EC
CORP
US
N
1
N
N
N
Zentalis Pharmaceuticals Inc
N/A
Zentalis Pharmaceuticals Inc
98943L107
915673.00000000
NS
USD
61020448.72000000
0.316254107969
Long
EC
CORP
US
N
1
N
N
N
LUMICKS TECH SER D CVT PFD STOCK PP
N/A
LUMICKS TECH SER D CVT PFD STOCK PP
000000000
4954.00000000
NS
USD
8875383.29000000
0.045998947633
Long
EP
CORP
US
Y
3
N
N
N
Cara Therapeutics Inc
549300COVOY41P0GZ881
Cara Therapeutics Inc
140755109
383715.00000000
NS
USD
5928396.75000000
0.030725434918
Long
EC
CORP
US
N
1
N
N
N
Atea Pharmaceuticals Inc
N/A
Atea Pharmaceuticals Inc
04683R106
877193.00000000
NS
USD
30754386.58000000
0.159392487240
Long
EC
CORP
US
N
1
N
N
N
HCA HEALTHCARE INC
529900PH4ZGUH2MNEU89
HCA HEALTHCARE INC
40412C101
1150869.00000000
NS
USD
279338923.68000000
1.447745534204
Long
EC
CORP
US
N
1
N
N
N
SCRIBE THERA SER B CVT PFD STOCK PP
N/A
SCRIBE THERA SER B CVT PFD STOCK PP
000000000
1027755.00000000
NS
USD
6219253.83000000
0.032232876248
Long
EP
CORP
US
Y
3
N
N
N
SOMALOGIC INC
549300D3W3Q8CN30YO25
CM LIFE SCIENCES II -CW27
83444K113
110601.00000000
NS
USD
381573.45000000
0.001977602157
Long
EC
CORP
US
N
1
N
N
N
Hologic Inc
549300DYP6F5ZJL0LB74
Hologic Inc
436440101
2907559.00000000
NS
USD
214606929.79000000
1.112255392551
Long
EC
CORP
US
N
1
N
N
N
RING THERA SER B CVT PFD STOCK PP
N/A
RING THERA SER B CVT PFD STOCK PP
000000000
978705.00000000
NS
USD
9004086.00000000
0.046665982400
Long
EP
CORP
US
Y
3
N
N
N
iRhythm Technologies Inc
549300FJI72RJGDQS384
iRhythm Technologies Inc
450056106
284041.00000000
NS
USD
16633440.96000000
0.086207069000
Long
EC
CORP
US
N
1
N
N
N
Sage Therapeutics Inc
5493000JX4BJS9W6CN35
Sage Therapeutics Inc
78667J108
433051.00000000
NS
USD
19188489.81000000
0.099449264229
Long
EC
CORP
US
N
1
N
N
N
AstraZeneca PLC
PY6ZZQWO2IZFZC3IOL08
AstraZeneca PLC
046353108
6584457.00000000
NS
USD
395462487.42000000
2.049585652314
Long
EC
CORP
GB
N
1
N
N
N
CARIS LIFE SCIENCES SER C CVT PFD PP
N/A
CARIS LIFE SCIENCES SER C CVT PFD PP
000000000
3758668.00000000
NS
USD
30445210.80000000
0.157790104554
Long
EP
CORP
US
Y
3
N
N
N
KARDIUM SERIES D6 CVT PFD STOCK PP
N/A
KARDIUM SERIES D6 CVT PFD STOCK PP
000000000
12320393.00000000
NS
USD
12515548.03000000
0.064865033951
Long
EP
CORP
US
Y
3
N
N
N
Tenaya Therapeutics Inc
N/A
Tenaya Therapeutics Inc
87990A106
296851.00000000
NS
USD
6129973.15000000
0.031770156252
Long
EC
CORP
US
N
1
N
N
N
2021-11-23
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
Alan S. Dupski
Alan S. Dupski
Treasurer & Vice President
XXXX
NPORT-EX
2
70F1TRP093021.htm
T.
ROWE
PRICE
Health
Sciences
Fund
September
30,
2021
(Unaudited)
Portfolio
of
Investments
‡
Shares
$
Value
(Cost
and
value
in
$000s)
‡
COMMON
STOCKS
96.4%
BIOTECHNOLOGY
29.3%
Major
Biotechnology
6.3%
Alkermes (1)
76,805
2,369
Amgen
634,354
134,895
Biogen (1)
526,309
148,940
BioNTech,
ADR (1)
888,020
242,421
Exact
Sciences (1)
1,328,703
126,825
Exact
Sciences
CMO
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
3,726,272
2,981
Exact
Sciences
Expense
Fund,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
3,795
4
Exact
Sciences
FDA
Milestone,
Acquisition
Date:
1/6/21,
Cost $— (1)(2)(3)
1,863,136
1,490
Neurocrine
Biosciences (1)
365,109
35,018
Novavax (1)
291,207
60,370
Seagen (1)
998,710
169,581
Vertex
Pharmaceuticals (1)
1,558,054
282,615
1,207,509
Other
Biotechnology
23.0%
AADI
Biosciences,
Acquisition
Date:
8/27/21,
Cost $5,305 (1)(3)
405,655
11,318
AC
Immune (1)
335,619
2,252
ACADIA
Pharmaceuticals (1)
1,096,469
18,212
Acceleron
Pharma (1)
1,526,603
262,728
Acerta
Future
Payments,
EC,
Acquisition
Date:
6/30/21,
Cost $25,373 (1)(2)(3)
25,372,879
22,772
Adaptive
Biotechnologies (1)
1,255,261
42,666
ADC
Therapeutics (1)
1,072,666
29,134
Agios
Pharmaceuticals (1)
570,909
26,347
Akero
Therapeutics (1)
320,250
7,158
Alector (1)
513,521
11,719
Allogene
Therapeutics (1)
1,265,834
32,532
Alnylam
Pharmaceuticals (1)
1,202,350
227,016
Annexon (1)
584,685
10,881
Apellis
Pharmaceuticals (1)
1,237,214
40,779
Arvinas (1)
549,763
45,180
Ascendis
Pharma,
ADR (1)
813,997
129,743
Atea
Pharmaceuticals (1)
933,093
32,714
Avidity
Biosciences (1)
963,638
23,734
BeiGene,
ADR (1)
260,250
94,471
Blueprint
Medicines (1)
730,223
75,074
C4
Therapeutics (1)
1,169,227
52,241
Centessa
Pharmaceuticals,
Acquisition
Date:
1/29/21,
Cost $7,143 (1)(3)
649,336
10,302
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Cerevel
Therapeutics
Holdings (1)
1,769,216
52,192
CM
Life
Sciences
III
SPAC/EQRX
PIPE (1)(4)
884,467
7,896
Cortexyme (1)
65,500
6,004
CRISPR
Therapeutics (1)
251,390
28,138
CureVac (1)
405,872
22,169
Day
One
Biopharmaceuticals (1)
200,661
4,762
Day
One
Biopharmaceuticals,
Acquisition
Date:
2/2/21,
Cost $3,646 (1)(3)
270,332
6,094
Deciphera
Pharmaceuticals (1)
96,883
3,292
Denali
Therapeutics (1)
1,432,855
72,288
DICE
Therapeutics (1)
474,448
15,538
Dicerna
Pharmaceuticals (1)
868,406
17,507
Enanta
Pharmaceuticals (1)
220,225
12,511
Evotec
(EUR) (1)
887,021
42,060
Exelixis (1)
4,276,740
90,410
Fate
Therapeutics (1)
1,206,059
71,483
Flame
Biosciences,
Acquisition
Date:
9/28/20,
Cost $5,500 (1)(2)
(3)
839,721
5,500
Generation
Bio (1)
1,736,219
43,527
Genmab
(DKK) (1)
215,537
94,173
Genmab,
ADR (1)
45,647
1,995
Ginkgo
Bioworks,
Acquisition
Date:
5/11/21,
Cost $5,479 (1)(3)
547,946
6,033
Ginkgo
Bioworks,
Acquisition
Date:
6/30/19-9/9/19,
Cost $21,415 (1)(3)
7,090,407
78,069
Ginkgo
Bioworks,
Earn
Out
Shares
$12.50,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,707
1,770
Ginkgo
Bioworks,
Earn
Out
Shares
$15.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706
1,701
Ginkgo
Bioworks,
Earn
Out
Shares
$17.50,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706
1,638
Ginkgo
Bioworks,
Earn
Out
Shares
$20.00,
Acquisition
Date:
9/17/21,
Cost $— (1)(3)
212,706
1,581
Global
Blood
Therapeutics (1)
159,954
4,076
IGM
Biosciences (1)
377,037
24,794
Imago
Biosciences (1)
240,093
4,809
Imago
Biosciences,
Acquisition
Date:
11/12/20,
Cost $5,370 (1)(3)
529,300
10,072
Immuneering (1)(5)
401,531
10,661
Immuneering,
Series
B,
Acquisition
Date:
12/21/20-5/4/21,
Cost $7,155 (1)(3)(5)
974,629
24,583
Immunocore
Holdings,
ADR (1)
304,616
11,292
Incyte (1)
2,310,007
158,882
Insmed (1)
2,316,374
63,793
Intellia
Therapeutics (1)
475,904
63,843
Ionis
Pharmaceuticals (1)
1,308,767
43,896
Iovance
Biotherapeutics (1)
1,467,698
36,193
IVERIC
bio (1)
2,537,772
41,213
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Karuna
Therapeutics (1)
427,366
52,280
Kodiak
Sciences (1)
1,364,585
130,973
Kronos
Bio (1)
552,898
11,589
Kymera
Therapeutics (1)
758,404
44,549
Longboard
Pharmaceuticals (1)(5)
780,435
6,954
Lonza
Group
(CHF)
77,625
58,227
MeiraGTx
Holdings (1)
494,331
6,515
Mersana
Therapeutics (1)
241,556
2,278
Mirati
Therapeutics (1)
702,359
124,254
Moderna (1)
1,276,162
491,144
Monte
Rosa
Therapeutics (1)
393,209
8,761
Monte
Rosa
Therapeutics,
Inc.,
Acquisition
Date:
3/11/21,
Cost $7,109 (1)(3)
679,381
14,380
Novocure (1)
563,219
65,429
Nurix
Therapeutics (1)
729,228
21,848
Prelude
Therapeutics (1)
328,791
10,275
Progenic
Pharmaceuticals,
CVR
842,223
41
Protagonist
Therapeutics (1)
388,176
6,878
Prothena (1)
1,006,244
71,675
PTC
Therapeutics (1)
414,054
15,407
Radius
Health (1)
507,175
6,294
RAPT
Therapeutics (1)
738,777
22,939
Reata
Pharmaceuticals,
Class
A (1)
186,798
18,794
Regeneron
Pharmaceuticals (1)
447,297
270,695
REGENXBIO (1)
238,760
10,009
Relay
Therapeutics (1)
370,846
11,693
Repligen (1)
137,815
39,827
Replimune
Group (1)
1,248,619
37,009
REVOLUTION
Medicines (1)
848,590
23,345
Rocket
Pharmaceuticals (1)
694,370
20,755
Sage
Therapeutics (1)
433,051
19,188
Sarepta
Therapeutics (1)
279,992
25,894
Scholar
Rock
Holding (1)
952,830
31,462
Seres
Therapeutics (1)
471,039
3,278
Stoke
Therapeutics (1)
254,758
6,481
Tenaya
Therapeutics (1)
296,851
6,130
Tenaya
Therapeutics,
Acquisition
Date:
12/17/20,
Cost $5,355 (1)
(3)
430,747
8,450
Turning
Point
Therapeutics (1)
531,122
35,282
Ultragenyx
Pharmaceutical (1)
1,525,947
137,625
uniQure (1)
416,122
13,320
Vividion
Therapeutics,
EC,
Acquisition
Date:
8/25/21,
Cost $— (1)
(2)
291,060
288
Vividion
Therapeutics,
Milestone
Payment,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
2,328,482
1,138
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Vividion
Therapeutics,
Milestone
Payment,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
1,746,361
1,024
Vividion
Therapeutics,
Milestone
Payment
3,
Acquisition
Date:
8/25/21,
Cost $— (1)(2)(3)
1,746,361
711
Xencor (1)
988,502
32,284
Zai
Lab,
ADR (1)
436,922
46,047
Zentalis
Pharmaceuticals (1)
915,673
61,020
Zymeworks (1)
490,021
14,230
4,444,080
Total
Biotechnology
5,651,589
CONSUMER
NONDURABLES
0.2%
Hospital
Supplies/Hosp
Management
0.2%
PROCEPT
BioRobotics (1)
268,312
10,236
PROCEPT
BioRobotics,
Acquisition
Date:
6/10/21,
Cost $13,279 (1)(3)
694,834
25,183
Total
Consumer
Nondurables
35,419
LIFE
SCIENCES
14.3%
Life
Sciences
14.3%
Abcam
(GBP) (1)
1,471,081
29,485
Agilent
Technologies
2,218,531
349,485
Berkeley
Lights (1)
331,312
6,481
Bio-Techne
118,351
57,349
Bruker
2,029,650
158,516
Danaher
2,423,520
737,816
Invitae (1)
901,387
25,626
MaxCyte (1)
422,700
5,161
Mettler-Toledo
International (1)
45,060
62,064
Olink
Holding,
ADR (1)
1,693,859
41,076
Ortho
Clinical
Diagnostics
Holdings (1)
3,577,780
66,117
Pacific
Biosciences
of
California (1)
2,701,237
69,017
Pacific
Biosciences
of
California,
Acquisition
Date:
7/21/21,
Cost $9,789 (1)(3)
365,964
8,883
Quanterix (1)
596,234
29,687
Quantum-Si (1)
1,866,008
15,563
Quidel (1)
436,942
61,674
Rapid
Micro
Biosystems,
Acquisition
Date:
3/9/21,
Cost $6,665 (1)
(3)
370,289
6,497
Rapid
Micro
Biosystems,
Class
A (1)
336,580
6,217
Schrodinger (1)
207,182
11,329
Seer (1)
2,630,514
90,832
SomaLogic (1)
551,066
6,828
SomaLogic,
Acquisition
Date:
11/20/20-9/15/21,
Cost $15,668 (1)
(3)
3,873,442
45,592
SomaLogic,
Acquisition
Date:
3/29/21,
Cost $7,566 (1)(3)
756,585
8,905
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
SomaLogic,
Warrants,
2/3/21 (1)
110,601
382
SomaLogic,
Earn
Out
Shares
$20,
Acquisition
Date:
9/2/21,
Cost $— (1)(3)
3,873,442
321
Thermo
Fisher
Scientific
1,422,670
812,814
Twist
Bioscience (1)
398,661
42,645
Total
Life
Sciences
2,756,362
MISCELLANEOUS
0.4%
Miscellaneous
0.4%
Health
Sciences
Acquisitions
Corp
2 (1)
688,861
6,813
Helix
Acquisition,
Class
A (1)(5)
639,149
6,308
Revolution
Healthcare
Acquisition (1)
1,738,886
17,128
Royalty
Pharma,
Class
A
1,597,128
57,720
Total
Miscellaneous
87,969
PHARMACEUTICALS
9.6%
European
Major
-
Pharmaceuticals
0.5%
Merck
(EUR)
447,337
96,821
Zeneca,
CVR,
Acquisition
Date:
7/18/13,
Cost $0 (1)(2)(3)
375,635
—
96,821
Major
Pharmaceuticals
9.1%
AbbVie
2,638,952
284,664
AstraZeneca,
ADR
6,584,457
395,462
Daiichi
Sankyo
(JPY)
1,400,200
37,219
Eisai
(JPY)
344,900
25,836
Eli
Lilly
2,243,718
518,411
Merck
4,520,546
339,538
PMV
Pharmaceuticals (1)
96,760
2,883
Roche
Holding
(CHF)
430,837
157,243
1,761,256
Specialty
Pharmaceuticals
0.0%
Cara
Therapeutics (1)
383,715
5,928
5,928
Total
Pharmaceuticals
1,864,005
PRODUCTS
&
DEVICES
18.1%
Implants
8.8%
AtriCure (1)
305,070
21,218
Becton
Dickinson
&
Company
980,714
241,079
Intuitive
Surgical (1)
738,824
734,502
iRhythm
Technologies (1)
284,041
16,633
Stryker
1,682,049
443,590
Teleflex
405,745
152,783
Verily
Life
Sciences,
Series
B,
Acquisition
Date:
1/23/19,
Cost $13,998 (1)(2)(3)
113,564
14,845
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Zimmer
Biomet
Holdings
444,930
65,120
1,689,770
Other
Products
&
Devices
9.3%
10X
Genomics,
Class
A (1)
503,125
73,245
Alcon
(CHF)
512,034
41,460
Argenx,
ADR (1)
824,888
249,116
Avantor (1)
4,373,940
178,894
Burning
Rock
Biotech,
ADR (1)
456,624
8,164
Catalent (1)
804,457
107,049
Cooper
197,335
81,561
Dexcom (1)
284,357
155,503
Hologic (1)
2,907,559
214,607
ICU
Medical (1)
7,833
1,828
Inari
Medical (1)
167,497
13,584
Insulet (1)
313,825
89,199
Lantheus
Holdings (1)
878,190
22,552
Nevro (1)
245,132
28,528
Outset
Medical (1)
641,577
31,720
Pax
Labs,
Class
A,
Acquisition
Date:
4/18/19,
Cost $31,622 (1)(2)
(3)
8,397,988
10,665
Penumbra (1)
546,904
145,750
Shockwave
Medical (1)
1,000,171
205,915
Warby
Parker,
Class
A (1)
2,443,421
129,624
1,788,964
Total
Products
&
Devices
3,478,734
SERVICES
20.5%
Distribution
0.3%
Option
Care
Health (1)
1,666,189
40,422
Shop
Apotheke
Europe
(EUR) (1)
68,332
10,062
50,484
Information
0.3%
Definitive
Healthcare (1)
615,230
26,350
Sema4
Holdings (1)
1,419,923
10,777
Sema4
Holdings,
Warrants,
10/23/20 (1)
253,101
537
Sophia
Genetics (1)
1,146,130
20,092
57,756
Information
1.9%
Doximity,
Class
A (1)(5)
574,338
46,349
Doximity,
Series
C,
Acquisition
Date:
4/10/14,
Cost $4,993 (1)(3)
(5)
2,071,266
158,793
Veeva
Systems,
Class
A (1)
594,731
171,384
376,526
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Other
Services
3.3%
Accolade (1)
444,589
18,748
Agiliti (1)
1,604,221
30,544
Certara (1)
896,790
29,684
Elanco
Animal
Health (1)
930,291
29,667
Guardant
Health (1)
872,150
109,028
Multiplan (1)
1,988,518
11,195
Pennant
Group (1)
504,314
14,166
Phreesia (1)
1,174,872
72,490
West
Pharmaceutical
Services
652,954
277,205
Wuxi
Biologics
Cayman
(HKD) (1)
2,858,500
46,366
639,093
Payors
12.8%
Alignment
Healthcare (1)
2,570,009
41,069
Anthem
811,789
302,635
Bright
Health
Group,
Acquisition
Date:
9/16/20,
Cost $21,284 (1)
(3)
3,127,275
24,243
Centene (1)
4,396,641
273,955
Cigna
918,399
183,827
Humana
823,804
320,583
Molina
Healthcare (1)
665,900
180,665
UnitedHealth
Group
2,901,526
1,133,742
2,460,719
Providers
1.9%
agilon
health (1)
936,437
24,544
FS
Development
SPAC/Pardes
Bio
PIPE (1)(4)
530,954
4,755
HCA
Healthcare
1,150,869
279,339
Oak
Street
Health (1)
465,354
19,791
Surgery
Partners (1)
823,568
34,870
363,299
Total
Services
3,947,877
Total
Miscellaneous
Common
Stocks
4.0% (6)
776,610
Total
Common
Stocks
(Cost
$8,717,035)
18,598,565
CONVERTIBLE
PREFERRED
STOCKS
3.0%
BIOTECHNOLOGY
0.9%
Other
Biotechnology
0.9%
Affinivax,
Series
C,
Acquisition
Date:
1/6/21,
Cost $13,396 (1)(2)
(3)
424,076
13,396
Delfi
Diagnostics,
Series
A,
Acquisition
Date:
1/12/21,
Cost $4,465 (1)(2)(3)
2,152,801
4,465
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
FOG
Pharma,
Series
C,
Acquisition
Date:
1/11/21-8/2/21,
Cost $6,251 (1)(2)(3)
431,391
6,251
Generate
Bio,
Series
B,
Acquisition
Date:
9/2/21,
Cost $22,096 (1)
(2)(3)
1,864,632
22,096
Genesis
Therapeutics,
Series
A,
Acquisition
Date:
11/24/20,
Cost $4,236 (1)(2)(3)
829,412
4,236
Gyroscope
Therapeutics,
Series
C-1,
Acquisition
Date:
3/30/21,
Cost $8,178 (1)(2)(3)
3,555,744
8,178
Insitro,
Series
B,
Acquisition
Date:
5/21/20,
Cost $5,505 (1)(2)(3)
883,580
16,161
Insitro,
Series
C,
Acquisition
Date:
4/7/21,
Cost $10,762 (1)(2)(3)
588,382
10,762
Laronde,
Series
B,
Acquisition
Date:
7/28/21,
Cost $32,757 (1)(2)
(3)
1,169,887
32,757
Lianbio,
Series
A,
Acquisition
Date:
10/28/20,
Cost $11,481 (1)(2)
(3)
202,628
11,481
Nutcracker
Therapeutics,
Series
C,
Acquisition
Date:
8/27/21,
Cost $11,050 (1)(2)(3)
1,027,785
11,050
Prime
Medicine,
Series
B,
Acquisition
Date:
4/19/21,
Cost $7,119 (1)(2)(3)
1,625,121
7,119
Ring
Therapeutics,
Series
B,
Acquisition
Date:
4/12/21,
Cost $9,004 (1)(2)(3)
978,705
9,004
Scribe
Therapeutics,
Series
B,
Acquisition
Date:
3/17/21,
Cost $6,219 (1)(2)(3)
1,027,755
6,219
Theseus
Pharmaceuticals,
Series
B,
Acquisition
Date:
2/9/21,
Cost $4,456 (1)(3)
514,797
5,838
Treeline,
Series
A,
Acquisition
Date:
4/9/21,
Cost $7,220 (1)(2)(3)
922,369
7,220
Total
Biotechnology
176,233
CONSUMER
NONDURABLES
0.2%
Healthcare
Services
0.2%
Capsule,
Series
D,
Acquisition
Date:
4/7/21,
Cost $12,364 (1)(2)(3)
853,213
12,364
Color
Health,
Series
D,
Acquisition
Date:
12/17/20,
Cost $11,181 (1)(2)(3)
296,922
13,596
Color
Health,
Series
D-1,
Acquisition
Date:
1/13/20,
Cost $9,358 (1)(2)(3)
438,696
20,088
Total
Consumer
Nondurables
46,048
LIFE
SCIENCES
0.7%
Life
Sciences
0.7%
Clear
Labs,
Series
C,
Acquisition
Date:
5/13/21,
Cost $13,294 (1)
(2)(3)
3,830,773
13,294
Element
Biosciences,
Series
C,
Acquisition
Date:
6/21/21,
Cost $17,704 (1)(2)(3)
861,217
17,704
Inscripta,
Series
E,
Acquisition
Date:
3/30/21,
Cost $12,829 (1)(2)
(3)
1,452,941
12,829
Lumicks
Tech,
Series
D,
Acquisition
Date:
4/14/21,
Cost $8,875 (1)(2)(3)
4,954
8,875
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
National
Resilience,
Series
B,
Acquisition
Date:
10/23/20,
Cost $16,458 (1)(2)(3)
1,204,832
53,507
National
Resilience,
Series
C,
Acquisition
Date:
6/9/21,
Cost $18,957 (1)(2)(3)
426,855
18,957
Total
Life
Sciences
125,166
PRODUCTS
&
DEVICES
0.1%
Capital
Equipment
0.0%
Reflexion
Medical,
Acquisition
Date:
4/3/20,
Cost $2,142 (1)(2)(3)
1,123,437
2,561
Reflexion
Medical,
Series
C,
1/2/24,
Acquisition
Date:
4/3/18,
Cost $4,243 (1)(2)(3)
2,507,885
5,718
8,279
Implants
0.1%
Kardium,
Series
D-5,
Acquisition
Date:
11/29/18,
Cost $8,574 (1)
(2)(3)(5)
8,849,057
8,989
Kardium,
Series
D-6,
Acquisition
Date:
1/8/21,
Cost $12,516 (1)
(2)(3)(5)
12,320,393
12,516
21,505
Total
Products
&
Devices
29,784
SERVICES
1.1%
Other
Services
1.0%
Caris
Life
Sciences,
Series
C,
Acquisition
Date:
8/14/20,
Cost $10,374 (1)(2)(3)
3,758,668
30,445
Caris
Life
Sciences,
Series
D,
Acquisition
Date:
5/11/21,
Cost $18,471 (1)(2)(3)
2,280,334
18,471
Freenome
Holdings,
Series
B,
Acquisition
Date:
6/24/19,
Cost $7,103 (1)(2)(3)
1,558,570
10,307
Freenome
Holdings,
Series
C,
Acquisition
Date:
8/14/20,
Cost $6,139 (1)(2)(3)
928,231
6,139
PrognomIQ,
Series
A-4,
Acquisition
Date:
11/15/19,
Cost $1,356 (1)(2)(3)(5)
593,540
1,356
PrognomIQ,
Series
A-5,
Acquisition
Date:
5/12/20,
Cost $1,174 (1)
(2)(3)(5)
513,797
1,174
PrognomIQ,
Series
B,
Acquisition
Date:
9/11/20,
Cost $8,533 (1)
(2)(3)(5)
3,734,140
8,533
Tempus
Labs,
Series
D,
1/2/24,
Acquisition
Date:
3/16/18,
Cost $8,876 (1)(2)(3)
946,886
53,000
Tempus
Labs,
Series
E,
Acquisition
Date:
8/23/18,
Cost $10,607 (1)(2)(3)
633,505
36,166
Tempus
Labs,
Series
F,
Acquisition
Date:
4/30/19,
Cost $4,279 (1)
(2)(3)
172,826
9,948
Tempus
Labs,
Series
G,
Acquisition
Date:
2/6/20,
Cost $4,284 (1)
(2)(3)
111,715
6,462
T.
ROWE
PRICE
Health
Sciences
Fund
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Tempus
Labs,
Series
G-2,
Acquisition
Date:
11/19/20,
Cost $6,720 (1)(2)(3)
117,271
6,720
188,721
Providers
0.1%
Honor
Technology,
Series
D,
Acquisition
Date:
10/16/20,
Cost $7,539 (1)(2)(3)
3,130,941
9,898
Honor
Technology,
Series
E,
Acquisition
Date:
9/29/21,
Cost $6,626 (1)(2)(3)
2,095,807
6,626
16,524
Total
Services
205,245
Total
Convertible
Preferred
Stocks
(Cost
$414,771)
582,476
PREFERRED
STOCKS
0.7%
LIFE
SCIENCES
0.7%
Life
Sciences
0.7%
Sartorius
(EUR)
195,622
124,535
Total
Life
Sciences
124,535
Total
Preferred
Stocks
(Cost
$28,101)
124,535
SHORT-TERM
INVESTMENTS
0.2%
Money
Market
Funds
0.2%
T.
Rowe
Price
Government
Reserve
Fund,
0.05% (5)(7)
34,557,789
34,558
Total
Short-Term
Investments
(Cost
$34,558)
34,558
Total
Investments
in
Securities
100.3%
(Cost
$9,194,465)
$
19,340,134
Other
Assets
Less
Liabilities
(0.3)%
(51,806)
Net
Assets
100.0%
$
19,288,328
T.
ROWE
PRICE
Health
Sciences
Fund
‡
Shares
are
denominated
in
U.S.
dollars
unless
otherwise
noted.
(1)
Non-income
producing
(2)
Level
3
in
fair
value
hierarchy.
(3)
Security
cannot
be
offered
for
public
resale
without
first
being
registered
under
the
Securities
Act
of
1933
and
related
rules
("restricted
security").
Acquisition
date
represents
the
day
on
which
an
enforceable
right
to
acquire
such
security
is
obtained
and
is
presented
along
with
related
cost
in
the
security
description.
The
fund
has
registration
rights
for
certain
restricted
securities.
Any
costs
related
to
such
registration
are
borne
by
the
issuer.
The
aggregate
value
of
restricted
securities
(excluding
144A
holdings)
at
period
end
amounts
to
$1,098,014
and
represents
5.7%
of
net
assets.
(4)
A
portion
of
the
position
represents
an
unfunded
commitment;
a
liability
to
fund
the
commitment
has
been
recognized.
The
fund's
total
unfunded
commitment
at
September
30,
2021,
was
$14,154
and
was
valued
at
$12,651
(0.1%
of
net
assets).
(5)
Affiliated
Companies
(6)
The
identity
of
certain
securities
has
been
concealed
to
protect
the
fund
while
it
completes
a
purchase
or
selling
program
for
the
securities.
(7)
Seven-day
yield
ADR
American
Depositary
Receipts
CHF
Swiss
Franc
CVR
Contingent
Value
Rights
DKK
Danish
Krone
EC
Escrow
CUSIP;
represents
a
beneficial
interest
in
a
residual
pool
of
assets;
the
amount
and
timing
of
future
distributions,
if
any,
is
uncertain;
when
presented,
interest
rate
and
maturity
date
are
those
of
the
original
security.
EUR
Euro
GBP
British
Pound
HKD
Hong
Kong
Dollar
JPY
Japanese
Yen
PIPE
Private
Investment
in
Public
Equity
SPAC
Special
Purpose
Acquisition
Company
T.
ROWE
PRICE
Health
Sciences
Fund
AFFILIATED
COMPANIES
($000s)
The
fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
1940
Act,
an
affiliated
company
is
one
in
which
the
fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
that
is
under
common
ownership
or
control.
The
following
securities
were
considered
affiliated
companies
for
all
or
some
portion
of
the
nine
months
ended
September
30,
2021.
Net
realized
gain
(loss),
investment
income,
change
in
net
unrealized
gain/loss,
and
purchase
and
sales
cost
reflect
all
activity
for
the
period
then
ended.
Affiliate
Net
Realized
Gain
(Loss)
Change
in
Net
Unrealized
Gain/Loss
Investment
Income
Doximity,
Class
A
$
—
$
27,028
$
—
Doximity,
Series
C
—
115,038
—
Helix
Acquisition,
Class
A
—
(614)
—
Immuneering
—
4,638
—
Immuneering,
Series
B
—
17,427
—
Kardium,
Series
D-5
—
415
—
Kardium,
Series
D-6
—
—
—
Longboard
Pharmaceuticals
(14)
(512)
—
Longboard
Pharmaceuticals,
Series
A
—
—
—
PrognomIQ,
Series
A-4
—
—
—
PrognomIQ,
Series
A-5
—
—
—
PrognomIQ,
Series
B
—
—
—
Seer ++
4,572
79,326
—
T.
Rowe
Price
Government
Reserve
Fund,
0.05%
—
—
16
Affiliates
not
held
at
period
end
—
(136,935)
—
Totals
$
4,558#
$
105,811
$
16+
T.
ROWE
PRICE
Health
Sciences
Fund
The
accompanying
notes
are
an
integral
part
of
this
Portfolio
of
Investments.
AFFILIATED
COMPANIES
(CONTINUED)
($000s)
Supplementary
Investment
Schedule
Affiliate
Value
12/31/20
Purchase
Cost
Sales
Cost
Value
09/30/21
Doximity,
Class
A
$
—
$
19,321
$
—
$
46,349
Doximity,
Series
C
*
—
—
158,793
Helix
Acquisition,
Class
A
*
—
—
6,308
Immuneering
—
6,023
—
10,661
Immuneering,
Series
B
—
7,156
—
24,583
Kardium,
Series
D-5
*
—
—
8,989
Kardium,
Series
D-6
—
12,516
—
12,516
Longboard
Pharmaceuticals
—
7,498
32
6,954
Longboard
Pharmaceuticals,
Series
A
4,157
—
4,157
—
PrognomIQ,
Series
A-4
1,356
—
—
1,356
PrognomIQ,
Series
A-5
1,174
—
—
1,174
PrognomIQ,
Series
B
8,533
—
—
8,533
Seer ++
15,584
—
4,078
90,832
Seer,
Class
A
136,935
—
—
—
T.
Rowe
Price
Government
Reserve
Fund,
0.05%
6,500
¤
¤
34,558
Total
$
411,606^
#
Capital
gain
distributions
from
mutual
funds
represented
$0
of
the
net
realized
gain
(loss).
++
Includes
previously
reported
affiliates
Seer
and
Seer,
Class
A
acquired
through
a
corporate
action.
+
Investment
income
comprised
$16
of
dividend
income
and
$0
of
interest
income.
¤
Purchase
and
sale
information
not
shown
for
cash
management
funds.
^
The
cost
basis
of
investments
in
affiliated
companies
was
$141,607.
*
On
the
date
indicated,
issuer
was
held
but
not
considered
an
affiliated
company.
T.
ROWE
PRICE
Health
Sciences
Fund
Unaudited
Notes
to
Portfolio
of
Investments
T.
Rowe
Price
Health
Sciences
Fund,
Inc. (the
fund) is
registered
under
the
Investment
Company
Act
of
1940
(the
1940
Act)
as
an
open-end
management
investment
company
and
follows
accounting
and
reporting
guidance
of
the
Financial
Accounting
Standards
Board
Accounting
Standards
Codification
Topic
946.
The
accompanying
Portfolio
of
Investments
was
prepared
in
accordance
with
accounting
principles
generally
accepted
in
the
United
States
of
America
(GAAP).
For
additional
information
on
the
fund’s
significant
accounting
policies
and
investment
related
disclosures,
please
refer
to
the
fund’s most
recent
semiannual
or
annual
shareholder
report
and
its
prospectus.
VALUATION
Fair
Value
The
fund’s
financial
instruments
are
valued
at
the
close
of
the
New
York
Stock
Exchange
(NYSE),
normally
4
p.m.
ET,
each
day
the
NYSE
is
open
for
business,
and
are
reported
at
fair
value,
which
GAAP
defines
as
the
price
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date. The
T.
Rowe
Price
Valuation
Committee
(the
Valuation
Committee)
is
an
internal
committee
that
has
been
delegated
certain
responsibilities
by
the
fund’s
Board
of
Directors
(the
Board)
to
ensure
that
financial
instruments
are
appropriately
priced
at
fair
value
in
accordance
with
GAAP
and
the
1940
Act.
Subject
to
oversight
by
the
Board,
the
Valuation
Committee
develops
and
oversees
pricing-related
policies
and
procedures
and
approves
all
fair
value
determinations.
Specifically,
the
Valuation
Committee
establishes
policies
and
procedures
used
in
valuing
financial
instruments,
including
those
which
cannot
be
valued
in
accordance
with
normal
procedures
or
using
pricing
vendors;
determines
pricing
techniques,
sources,
and
persons
eligible
to
effect
fair
value
pricing
actions;
evaluates
the
services
and
performance
of
the
pricing
vendors;
oversees
the
pricing
process
to
ensure
policies
and
procedures
are
being
followed;
and
provides
guidance
on
internal
controls
and
valuation-related
matters.
The
Valuation
Committee
provides
periodic
reporting
to
the
Board
on
valuation
matters.
Various
valuation
techniques
and
inputs
are
used
to
determine
the
fair
value
of
financial
instruments.
GAAP
establishes
the
following
fair
value
hierarchy
that
categorizes
the
inputs
used
to
measure
fair
value:
Level
1
–
quoted
prices
(unadjusted)
in
active
markets
for
identical
financial
instruments
that
the
fund
can
access
at
the
reporting
date
T.
ROWE
PRICE
Health
Sciences
Fund
Level
2
–
inputs
other
than
Level
1
quoted
prices
that
are
observable,
either
directly
or
indirectly
(including,
but
not
limited
to,
quoted
prices
for
similar
financial
instruments
in
active
markets,
quoted
prices
for
identical
or
similar
financial
instruments
in
inactive
markets,
interest
rates
and
yield
curves,
implied
volatilities,
and
credit
spreads)
Level
3
–
unobservable
inputs
(including
the fund’s
own
assumptions
in
determining
fair
value)
Observable
inputs
are
developed
using
market
data,
such
as
publicly
available
information
about
actual
events
or
transactions,
and
reflect
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
Unobservable
inputs
are
those
for
which
market
data
are
not
available
and
are
developed
using
the
best
information
available
about
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
GAAP
requires
valuation
techniques
to
maximize
the
use
of
relevant
observable
inputs
and
minimize
the
use
of
unobservable
inputs.
When
multiple
inputs
are
used
to
derive
fair
value,
the
financial
instrument
is
assigned
to
the
level
within
the
fair
value
hierarchy
based
on
the
lowest-level
input
that
is
significant
to
the
fair
value
of
the
financial
instrument.
Input
levels
are
not
necessarily
an
indication
of
the
risk
or
liquidity
associated
with
financial
instruments
at
that
level
but
rather
the
degree
of
judgment
used
in
determining
those
values.
Valuation
Techniques
Equity
securities,
including
exchange-traded
funds, listed
or
regularly
traded
on
a
securities
exchange
or
in
the
over-the-counter
(OTC)
market
are
valued
at
the
last
quoted
sale
price
or,
for
certain
markets,
the
official
closing
price
at
the
time
the
valuations
are
made.
OTC
Bulletin
Board
securities
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices.
A
security
that
is
listed
or
traded
on
more
than
one
exchange
is
valued
at
the
quotation
on
the
exchange
determined
to
be
the
primary
market
for
such
security.
Listed
securities
not
traded
on
a
particular
day
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices
for
domestic
securities
and
the
last
quoted
sale
or
closing
price
for
international
securities.
The
last
quoted
prices
of
non-U.S.
equity
securities
may
be
adjusted
to
reflect
the
fair
value
of
such
securities
at
the
close
of
the
NYSE,
if
the
fund
determines
that
developments
between
the
close
of
a
foreign
market
and
the
close
of
the
NYSE
will
affect
the
value
of
some
or
all
of
its
portfolio
securities.
Each
business
day,
the
fund
uses
information
from
outside
pricing
services
to
evaluate
and,
if
appropriate,
decide whether
it
is
necessary
to
adjust
quoted
prices
to
reflect
fair
value
by
reviewing
a
variety
of
factors,
including
developments
in
foreign
markets,
the
performance
of
U.S.
securities
markets,
and
the
performance
of
instruments
trading
in
U.S.
markets
that
represent
foreign
securities
and
baskets
of
foreign
securities. The
fund
uses
outside
pricing
services
T.
ROWE
PRICE
Health
Sciences
Fund
to
provide
it
with
quoted
prices
and
information
to
evaluate
or
adjust
those
prices.
The
fund
cannot
predict
how
often
it
will
use
quoted
prices
and
how
often
it
will
determine
it
necessary
to
adjust
those
prices
to
reflect
fair
value.
Investments
denominated
in
foreign
currencies
are
translated
into
U.S.
dollar
values
each
day
at
the
prevailing
exchange
rate,
using
the
mean
of
the
bid
and
asked
prices
of
such
currencies
against
U.S.
dollars
as
provided
by
an
outside
pricing
service.
Investments
in
mutual
funds
are
valued
at
the
mutual
fund’s
closing
NAV
per
share
on
the
day
of
valuation.
Investments
for
which
market
quotations
or
market-based
valuations
are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
as
determined
in
good
faith
by
the
Valuation
Committee,
in
accordance
with
fair
valuation
policies
and
procedures.
The
objective
of
any
fair
value
pricing
determination
is
to
arrive
at
a
price
that
could
reasonably
be
expected
from
a
current
sale.
Financial
instruments
fair
valued
by
the
Valuation
Committee
are
primarily
private
placements,
restricted
securities,
warrants,
rights,
and
other
securities
that
are
not
publicly
traded.
Factors
used
in
determining
fair
value
vary
by
type
of
investment
and
may
include
market
or
investment
specific
considerations.
The
Valuation
Committee
typically
will
afford
greatest
weight
to
actual
prices
in
arm’s
length
transactions,
to
the
extent
they
represent
orderly
transactions
between
market
participants,
transaction
information
can
be
reliably
obtained,
and
prices
are
deemed
representative
of
fair
value.
However,
the
Valuation
Committee
may
also
consider
other
valuation
methods
such
as
market-based
valuation
multiples;
a
discount
or
premium
from
market
value
of
a
similar,
freely
traded
security
of
the
same
issuer;
discounted
cash
flows;
yield
to
maturity;
or
some
combination.
Fair
value
determinations
are
reviewed
on
a
regular
basis
and
updated
as
information
becomes
available,
including
actual
purchase
and
sale
transactions
of
the
investment.
Because
any
fair
value
determination
involves
a
significant
amount
of
judgment,
there
is
a
degree
of
subjectivity
inherent
in
such
pricing
decisions,
and
fair
value
prices
determined
by
the
Valuation
Committee
could
differ
from
those
of
other
market
participants.
Valuation
Inputs
The
following
table
summarizes
the
fund’s
financial
instruments,
based
on
the
inputs
used
to
determine
their
fair
values
on
September
30,
2021
(for
further
detail
by
category,
please
refer
to
the
accompanying
Portfolio
of
Investments):
T.
ROWE
PRICE
Health
Sciences
Fund
Following
is
a
reconciliation
of
the
fund’s
Level
3
holdings
for
the
period ended
September
30,
2021.
Gain
(loss)
reflects
both
realized
and
change
in
unrealized
gain/
loss
on
Level
3
holdings
during
the
period,
if
any.
The
change
in
unrealized
gain/loss
on
Level
3
instruments
held
at
September
30,
2021,
totaled $80,099,000 for
the
period ended
September
30,
2021.
In
accordance
with
GAAP,
the
following
table
provides
quantitative
information
about
significant
unobservable
inputs
used
to
determine
the
fair
valuations
of
the
fund’s
Level
3
assets,
by
class
of
financial
instrument.
Because
the
Valuation
Committee
considers
a
wide
variety
of
factors
and
inputs,
both
observable
and
unobservable,
in
determining
fair
values,
the
unobservable
inputs
presented
do
not
reflect
all
inputs
significant
to
the
fair
value
determination.
($000s)
Level
1
Level
2
Level
3
Total
Value
Assets
Common
Stocks
$
17,423,858
$
1,113,289
$
61,418
$
18,598,565
Convertible
Preferred
Stocks
—
5,838
576,638
582,476
Preferred
Stocks
—
124,535
—
124,535
Short-Term
Investments
34,558
—
—
34,558
Total
$
17,458,416
$
1,243,662
$
638,056
$
19,340,134
($000s)
Beginning
Balance
12/31/20
Gain
(Loss)
During
Period
Total
Purchases
Total
Sales
Ending
Balance
9/30/21
Investment
in
Securities
Common
Stocks
$
87,007
$
375
$
51,575
$
(77,539)
$
61,418
Convertible
Preferred
Stocks
424,227
13,244
263,014
(123,847)
576,638
Total
$
511,234
$
13,619
$
314,589
$
(201,386)
$
638,056
T.
ROWE
PRICE
Health
Sciences
Fund
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Common
Stock
$
61,418
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
Uncertainty
1%-59%
30%
Decrease
Market
comparable
Enterprise
Value
to
Sales
Multiple
4.8x
–
21.8x
14.1x
Increase
Sales
Growth
Rate
11%-42%
29%
Increase
Enterprise
Value
to
Gross
Profit
Multiple
9.5x
–
15.4x
12.5x
Increase
Gross
Profit
Growth
Rate
13%
13%
Increase
Discount
for
Lack
of
Marketability
10%
10%
Decrease
Estimated
Liquidation
Value
Discount
for
lack
of
collectability
100%
100%
Decrease
Convertible
Preferred
Stocks
$
576,638
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
Cumulative
Preferred
Dividend
Rights
0%
-
2%
2%
Decrease
T.
ROWE
PRICE
Health
Sciences
Fund
#
No
quantitative
unobservable
inputs
significant
to
the
valuation
technique
were
created
by
the
fund’s
management.
*
Unobservable
inputs
were
weighted
by
the
relative
fair
value
of
the
instruments.
**
Represents
the
directional
change
in
the
fair
value
of
the
Level
3
investment(s)
that
would
have
resulted
from
an
increase
in
the
corresponding
input
at
period
end.
A
decrease
in
the
unobservable
input
would
have
had
the
opposite
effect.
Significant
increases
and
decreases
in
these
inputs
in
isolation
could
result
in
significantly
higher
or
lower
fair
value
measurements.
+
Valuation
techniques
may
change
in
order
to
reflect
management’s
judgment
of
current
market
participant
assumptions.
F114-054Q3
09/21
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Premium
for
Cumulative
Preferred
Dividend
Rights
0%
-
1%
1%
Increase